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Magnetic and plasmonic properties combined in a single nanostructure provide a 
synergy that is advantageous in a number of biomedical applications, such as contrast 
enhancement in multimodal imaging, simultaneous capture and detection of circulating 
tumor cells, and photothermal therapy of cancer. These applications have stimulated 
significant interest in development of magneto-plasmonic nanoparticles with optical 
absorbance in the near-infrared region and a strong magnetic moment. In this dissertation, 
we addressed this need to create a novel immunotargeted magneto-plasmonic 
nanoparticle platform. The nanostructures were synthetized by self-assembly of primary 
6 nm iron oxide core-gold shell particles, resulting in densely packed spherical 
nanoclusters. The close proximity of the primary particles in the nanoclusters generates a 
greatly improved response to an external magnetic field and strong near-infrared plasmon 
resonances. A procedure for antibody conjugation and PEGylation to the hybrid 
nanoparticles was developed for biomedical applications which require molecular and 
biocompatible targeting. Furthermore, we presented two biomedical applications based 
on the immunotargeted hybrid nanoparticle platform, including circulating tumor cell 
(CTC) detection and cell-based immunotherapy of cancer. In the CTC detection assays, 
rare cancer cells were specifically targeted by antibody-conjugated nanoparticles and 
 vii 
efficiently separated from normal blood cells by a magnetic force in a microfluidic 
chamber. The experiments in whole blood showed capture efficiency greater than 90% 
for a variety of cancers. We also explored photoacoustic imaging to detect nanoparticle-
labeled CTCs in whole blood. The results showed excellent sensitivity to delineate the 
distribution of hybrid nanoparticles on the cancer cells. Thus, these works paves the way 
for a novel CTC detection approach which utilizes immunotargeted magneto-plasmonic 
nanoclusters for a simultaneous magnetic capture and photoacoustic detection of CTCs. 
In another application, we introduced a novel approach to label cytotoxic T cells using 
the magnetic nanoparticles with an expectation to enhance T cell recruitment in tumor 
under external magnetic stimulus. A series of in vitro experiments demonstrated highly 
controllable manipulation of labeled T cells. Thus, these results highlight the promise of 
using our nanoparticle platform as a multifunctional probe to manipulate and track 
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Chapter 1: Introduction 
1.1 BACKGROUND ON CANCER MANAGEMENT 
The increase of survival rates for cancer patients significantly reflects 
improvements in early diagnosis, effective treatment, and/or appropriate monitoring.1-3 
The use of screening tools to recognize possible warning signs of cancer leads to early 
diagnosis. Over the past decades, several techniques have revolutionized the practice of 
medicine. For example, mammography is an x-ray examination to detect abnormalities of 
the breasts that may be breast cancer. The Pap smear test is to detect cervical cancer by 
collection of exfoliating epithelial cells from the cervical squamolcolumnar junction. 
Screening the blood level of prostate-specific antigen yields predictive value for prostate 
cancer. By using these examination techniques, abnormalities can be detected well before 
they produce clinical signs or symptoms.  
To date, there are many treatment options for patients who are diagnosed with 
cancer. Conventionally, surgery with radiation or chemotherapy have significantly 
reduced the morbidity and mortality associated with solid neoplasms.4-6 However, high 
rates of unwanted side effects are still the primary concern for patients.7, 8 Relapsing of 
advanced cancer may occur so that patients would be given lower doses of chemotherapy 
as maintenance therapy for a couple of years to keep the cancer from returning.9 With the 
attempt to improve deficiencies from current standard therapy, development of molecular 
specific therapies targets several biomarkers of cancer, such as human epidermal receptor 
(HER) 1 and 2, vascular endothelial growth factor receptor, and prostate-specific 
membrane antigen.10-13 More recently, an experimental anticancer therapy, called 
adoptive cell therapy (ACT), which attempts to enhance the natural cancer-fighting 
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ability of cytotoxic T cells has demonstrated high efficacy for the treatment of metastatic 
melanoma.14   
Along with the development of novel therapeutics aiming at complex pathways 
and mode of actions, methods to monitor the treatment response and predict the 
therapeutic success have been expanded beyond conventional response criteria, i.e. 
anatomic changes. Thus, monitoring response to cancer therapy at molecular or single 
cell level has gained popularity in recent years. Innovative imaging approaches, such as 
positron emission tomography allows longitudinal assessment of specific biological 
processes rather than anatomic changes in tumor size.15 Accurate quantitation of 
circulating cancer cells (CTC) in the bloodstream shows great potential to determine 
prognosis and predict the overall survival in metastatic breast cancer patients.16, 17 Overall, 
all these advanced techniques paved the way to improve our understanding of the 
underlying molecular and cellular features of cancers, thus contributing to better 
diagnosis, management and treatment of cancers. 
1.2 THE DEMAND OF HYBRID MAGNETO-PLASMONIC NANOPARTICLES 
The field of nanotechnology provides opportunities for development of novel 
hybrid nanomaterials which enable new approaches and methods in various biomedical 
applications including molecular imaging and therapy.18, 19 During the past few years, the 
combination of magnetic and plasmonic properties on nanoscale have drawn particular 
interest due to unique characteristics of each material.20, 21 Indeed, gold-based 
nanoparticles exhibit strong localized surface plasmon resonances in visible and near-
infrared (NIR) spectral regions; this property has been explored in a plethora of exciting 
applications ranging from molecular dark-field, reflectance and photoacoustic imaging to 
photothermal therapy and drug release.22-25 Similarly, superparamagnetic nanoparticles 
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are of great interest because of their applications in various cell and molecular separation 
assays; magneto-motive optical and ultrasound imaging; magnetic resonance imaging 
(MRI); and hyperthermia cancer treatment.26-29 
Recent reports have demonstrated a synergistic potential of combining plasmonic 
and superparamagnetic nanoparticles. For example, spherical gold shell/iron oxide core 
nanoparticles were used for molecular imaging of cancer cells overexpressing epidermal 
growth factor receptor (EGFR).30 Furthermore, cancer cells labeled with these 
nanoparticles were destructed by a 700 nm laser irradiation with a very high efficiency 
demonstrating theranostic capabilities of these agents. In another study, gold shell/iron 
oxide core nanoparticles were used in a highly sensitive magneto-motive dark-field 
optical imaging of cancer cells.31 In this case, the combination of bright plasmon 
resonance scattering from the gold shell and modulation of the optical signal by an 
external magnetic field was used to significantly increase imaging contrast. The same 
approach was used for the detection of single stellated gold nanoparticles containing a 
magnetic iron oxide core, demonstrating high sensitivity of this imaging approach.32 
More recently, magneto-plasmonic nanoparticles were used in development of a new 
imaging approach - magneto-photoacoustic imaging.27, 33 In this imaging method, a 
combination of plasmonic and magnetic properties of hybrid nanoparticles is used to 
greatly increase imaging contrast in cellular and molecular imaging at significant tissue 
depth.  
One emerging applications of magneto-plasmonic nanomaterials is a simultaneous 
capture and detection of CTCs. In initial experiments, two separate functionalized 
nanoparticles were used - magnetic iron oxide particles for cell capture and gold-plated 
carbon nanotubes for photoacoustic (PA) detection of the captured CTCs.34 These 
experiments showed the feasibility of capture and detection of breast cancer cells pre-
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injected into a live mouse bloodstream in vivo. However, the use of two different 
nanoparticles for capture and detection of CTCs can significantly limit efficacy of this 
approach because of a limited number of specific biomarkers which are overexpressed in 
cancer and the associated problem in funding two different biomarkers for each cancer 
type. Therefore, the latest approaches in this field have utilized hybrid magneto-
plasmonic nanoparticles.35, 36 Silica-coated gold nanorods adorned with iron-oxide 
nanoparticles and conjugated with folic acid molecules were used to demonstrate the 
feasibility of capture and PA detection of HeLa cancer cells under flow conditions.36 
HeLa cells were pre-labeled with the hybrid nanoparticles, fixed and, then, 
simultaneously captured and detected in flow at concentrations as low as one cell per mL. 
In another study, we synthesized immunotargeted 6 nm iron oxide shell/gold core 
nanoparticles for capture of cancer cells in whole blood.35 Skin, breast, or colon cancer 
cells were mixed with whole human blood at concentrations ranging from 2 to 200 
cells/mL, then, the immunotargeted nanoparticles were added to label cancer cells; the 
cells were captured in whole blood without any pre-processing steps using a permanent 
magnet and a flow chamber. Detection of the captured cells was carried out by taking 
advantage a strong scattering from the nanoparticles in dark-field optical imaging and by 
a standard fluorescent immunostaining. We showed the capture efficiency greater than 
90% when a mixture of two nanoparticles targeted to two cancer biomarkers per cell type 
was used. 
In sum, novel approaches to synthesize hybrid magneto-plasmonic nanoparticles 
with a high magnetic moment and strong plasmonic resonances in the red-NIR spectral 
region can lead to significant improvements in various biomedical applications, including 
sensitivity of multi-modal molecular imaging, specificity of targeted photothermal 
therapy, and capture efficacy of rare cells such as CTCs.  
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1.3 ROLES OF CTC DETECTION IN CANCER MANAGEMENT AND CURRENT DETECTION 
TECHNOLOGIES 
The origin of CTCs in the peripheral blood has been considered the detachment 
from primary solid tumor. CTCs then travel in bloodstream, colonize a new distant tissue, 
and form therein a new tumor mass.37 The process leads to the deadly aspect of cancer, 
metastasis, by compromising the functions of an organ, i.e. lung, brain, liver or bones. 
However, CTCs are thought very rare, estimated as one to few CTCs among millions of 
leukocytes and billions of erythrocytes.16 The presence of five or more CTCs in 7.5 mL 
blood correlated with poor clinical outcomes than the case of less than five CTCs.17 More 
recently, several studies have suggested that information provided by CTC count may be 
useful to stratify cancer stages and select therapeutics that could provide differential 
palliative benefit for patients.38, 39 In addition, the presence of one or more CTCs in 
chemonaive patients with non-metastatic breast cancer may predict early recurrence and 
decreased overall survival. Thus, creating a sensitive assay to access metastatic tumor 
cells may be able to determine individual prognosis, stratify cancer patients at-risk for 
systemic adjuvant anticancer therapies, and monitor the efficacy of these therapies. 
Currently, there are several assays described for the detection and enumeration of 
CTCs, relying on the physical properties, biomarker expression, or functional 
characteristics of CTCs.40 One of the most effective methods is antibody-based capture 
technologies that are usually carried out with antibodies against common biomarkers. The 
isolation is realized using an antibody-mediated substrate which CTCs are specifically 
interacted with and directly or indirectly captured. One of the systems, CellSearchTM, is 
the well-known and the first platform to gain FDA approval for prognosis in breast, 
prostate and colorectal cancer.16 Basically, the CellSearchTM system utilizes ferrofluids 
consisting of magnetic nanoparticles embedded by a polymeric layer coated with 
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antibodies against epithelial cell adhesion molecules (EpCAM).16, 17 After the positive 
selection of CTCs, the enriched cells are subsequently stained with fluorescent nuclear 
dye DAPI (4',6-diamidino-2-phenylindole), fluorescent antibody specific to CD45+ 
leukocytes (negative selection) and fluorescent antibodies to intracellular cytokeratins 8, 
18 and 19, which are specific to epithelial cells. A semi-automated, four colored 
microscope is used to identify CTC as DAPI positive, cytokeratin positive, and CD45 
negative.  
Physical properties of cells, such as size, mechanical plasticity, density, and 
dielectric properties, can be exploited to isolate CTCs from the blood. Size-based 
isolation mainly relies on the larger size of CTCs in comparison with blood cells. Several 
substrates, including membrane filter and microfluidic chips, with size selection function 
have been demonstrated.41, 42 Furthermore, the most sensitive CTC detection assay could 
be derived from nucleic acid-based approach which identifies specific DNA or mRNA 
molecules in the sample. The extracted substance from the enriched sample is employed 
in polymerase chain reaction to target CTC-specific genes correlated to either tissue-, 
organ-, or tumor-specific proteins or polypeptides.43 Approaches based on mRNA 
molecule are considered more effective since mRNA molecule is unstable and rapidly 
degraded in the circulation. Thus, the presence of mRNA expression can be associated 
with the living CTCs in the blood sample.44 
Despite these techniques show promise to provide desirable sensitivity of CTC 
detection, each of them could be a compromise. Highly sensitive methods may not be 
rapid or low-cost, whereas quicker tests are not necessarily effective. For example, 
several antibody-based capture assays have been realized to detect CTCs. Due to lack of 
a universal surface antigen for CTCs, a subpopulation of metastatic tumor cells could be 
potentially missed by using a single biomarker.45, 46 Furthermore, enrichment methods 
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based on the differentiation of cell size address the problem to reduce dependency on 
antigen expression. Although the assays are simple and label-free, the accuracy may be 
sacrificed because of the non-uniformity size of CTCs.47 In addition, microfluidic 
platform offers high CTC counts in cancer patients but slow flow rates lengthen the 
process to restrict clinical practice.40 Nucleic acid-based techniques with impressive 
sensitivity gain attention, yet its specificity could dampen its usage. False-positive signals 
could easily be derived from the inflammation, invasive diagnostic biopsies, or during the 
tumor resection surgeries.48 Thus, the best method for detection and isolation of CTCs 
still depends on the targeted application and resources. 
1.4 ROLES OF ADOPTIVE CELL THERAPY IN CANCER TREATMENT AND CURRENT 
STATUS 
Adoptive cell therapy has emerged as the most effective treatment for patients 
with metastatic melanoma.49 The basic concept of ACT is to generate large number of 
tumor-reactive T cells in patients with cancer, followed by transferring cultured tumor-
reactive T cells expanded in vitro into a properly prepared recipient who allows 
manipulation of the host to minimize inhibitory factors to support the transferred T cells. 
Of patients with metastatic melanoma refractory to all other treatments, approximate half 
of the patients experienced an objective response via ACT and some of them showed 
complete responses.50 
The high effectiveness of ACT on melanoma is due to that the natural course of 
tumor growth induces significant numbers of lymphocytes with anti-tumor activity.51 
These tumor infiltrating lymphocytes (TIL) can be isolated to provide a consistent source 
of T cells to expand in culture, thus enabling the identification of multiple melanoma 
associated antigen for immunotherapy. However, simply infusing large number of TILs 
along with Interleukin 2 only caused a third of patients to brief response.52 The decisive 
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improvement in efficacy was greatly enhanced by introduction of an immunodepleting 
preparative regimen given before the ACT.14 Lymphodepletion leads to elimination of T 
regulatory cells and other lymphocytes which compete homeostatic cytokines with the 
transferred cells. Thus, immunosuppressing the host immediately before ACT improves 
survival of transfer cells thus increases therapeutic efficacy.  
Despite the success on melanoma patients whose TIL can be isolated and 
expanded, ACT still remains challenging for patients who cannot grow TIL or patients 
with non-melanoma tumors. Until recently, the ability to genetically engineer 
lymphocytes opened possibility for the extension of ACT to patients with a variety of 
cancer.53 By modifying peripheral blood lymphocytes with new functions and specificity, 
such as classical major histocompatibility complex (MHC)-restricted T cell receptor or 
chimeric (antibody-based) antigen receptors (CARs), ACT showed improved antitumor 
effects and enhanced immune reconstitution on immunosuppressed cancer patients.54   
There are several issues that need to be addressed before ACT becomes a clinical 
fit into current modes of oncological practice. ACT is a highly personalized treatment 
which is labor intensive and requires laboratory expertise. Each patient receives 
individualized reagents so it contradicts the production paradigm of pharmaceutical or 
biotech companies. In addition, several lines of evidence showed that the cell delivery is 
still a major concern for ACT. For example, persistence of the transferred cells in vivo 
was short with barely 0.01% of transferred cells in the circulation after receiving ACT for 
one week.55 The homing efficiency of transferred T cells to tumor was disappointing for 
less than 1% migrating to the tumor, whereas the majority localized in the lung, liver, and 
spleen.56, 57 Therefore, new approaches are required for time effective and highly targeted 
cell delivery to tumor.  
 9 
1.5 OVERALL RESEARCH GOALS 
The overall goals of this dissertation are to develop a magneto-plasmonic 
nanoparticle platform, which can be applicable to the filed of cancer management 
including CTC detection and ACT for cancer. In Chapter 2, the build and characterization 
of an immunotargeted magneto-plasmonic nanoparticle platform is described. In Chapter 
3, the CTC detection assays are introduced which are based on the immunotargeted 
nanoparticle platform. In Chapter 4, the feasibility of magnetically guided cell delivery 
for ACT is explored. Finally, Chapter 5 lists the overall conclusions and future directions. 
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Chapter 2: Development of an Immunotargeted Magneto-Plasmonic 
Nanoparticle Platform  
2.1 INTRODUCTION 
Hybrid nanoparticles consisting of different materials with distinct physico-
chemical properties can open new opportunities in biomedical applications including 
multimodal molecular imaging, therapy delivery and monitoring, new screening and 
diagnostic assays.1-3 The combination of plasmonic and magnetic properties in a single 
nanoparticle is of particular interest because it provides a very strong light scattering and 
absorption cross-sections associated with plasmon resonances that are coupled with 
responsiveness to a magnetic field. For example, magneto-plasmonic nanoparticles were 
used to increase contrast in dark-field imaging of labeled cells by applying a temporal 
signal modulation via an external electromagnet.3-5 More recently, a similar principle was 
applied to development of a new imaging modality – magneto-photoacoustic imaging 
where magneto-plasmonic nanoparticles enable great improvement of contrast.6, 7 It was 
also shown that the hybrid nanoparticles can be used for simultaneous capture and 
detection of circulating tumor cells in whole blood and in vivo.8, 9 Furthermore, magneto-
plasmonic nanoparticles are promising theranostic agents which can be used for 
molecular specific optical and MR imaging combined with photothermal therapy of 
cancer cells.10 
Several approaches were explored for synthesis of magneto-plasmonic 
nanoparticles. For example, Yu et al. utilized decomposition and oxidation of Fe(CO)5 on 
the gold nanoparticles to form dumbbell-like bifunctional Au–Fe3O4 nanoparticles.11 
Wang et al. have synthesized gold-coated iron oxide nanoparticle by using thermal 
decomposition method.12 Some other approaches rely on coating polymer or amine 
functional molecules onto magnetic core nanoparticles followed by deposition of a gold 
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shell onto the polymer surface to create the hybrid particles.7, 13 In addition, iron-oxide 
nanoparticles were attached to gold nanorods via electrostatic interactions or a chemical 
reaction.14, 15 Although these approaches yield magneto-plasmonic nanostructures, they 
compromise to some extent properties of the magneto-plasmonic combination such as 
optical absorbance in the near-infrared (NIR) window or a strong magnetic moment, both 
of which are highly desirable in biomedical applications. For example, the dumbbell Au–
Fe3O4 nanoparticles have a plasmon resonance peak at 520 nm which limits their utility in 
vivo due to high tissue turbidity in this spectral range. Furthermore, the multi-step 
synthesis involving polymer coating for gold deposition is not facile. Uneven or low 
polymer coverage on the magnetic core can compromise the deposition of a gold shell. 
This approach is also limited to a single superparamagnetic moiety per a magneto-
plasmonic nanoparticle. In general, iron oxide nanoparticles exhibit superparamagnetic 
behavior in sizes up to about 20 to 30 nm in diameter, above which the particles become 
ferromagnetic that puts a limit on the magnetic moment of superparamagnetic 
nanoparticles which are based on a single iron oxide core. In addition, the magneto-
plasmonic nanoparticles produced by the current protocols are limited to just one11 or a 
few (less than 10)14, 15 superparamagnetic moieties (e.g., iron oxide nanoparticles) that is 
significantly less than those could be achieved in a densely packed nanostructure. The use 
of gold nanorods as a template for the deposition of iron oxide nanoparticles further 
requires careful optimization to ensure colloidal stability and there is significant 
variability in the number of iron oxide moieties per hybrid nanoparticle because of 
limited nanorod surface area. Therefore, there is great room for improving magnetic 
properties of the hybrid nanoparticles. Moreover, some of the protocols are relatively 
complex and require careful optimization in order to avoid aggregation of the particles 
during synthesis.14, 15     
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Novel approaches to synthesize hybrid nanoparticles with a high magnetic 
moment and strong absorbance in the red-NIR spectral region can lead to significant 
improvements in various biomedical applications including sensitivity of multi-modal 
molecular imaging, image guidance of photothermal therapy, and CTC assays. In this 
chapter, we describe a method for synthesis of magneto-plasmonic nanoparticles with a 
strong magnetic moment and a strong NIR absorbance that addresses major limitations of 
the current art (Figure 2.1). The synthesis has its origins in oil-in-water microemulsion 
method.16 It is based on assembly of nanoparticles of a desired size from a much smaller 
primary particles. This approach has been successfully used to produce nanostructures 
from a single material such as gold, iron oxide and semiconductor primary particles.16 We 
extended it to synthesis of magneto-plasmonic nanoparticles by, first, making 6 nm 
diameter gold shell/iron oxide core particles and, then, assembling the primary hybrid 
particles into the final spherical nanostructure. Assembling primary particles into 
nanoclusters not only allows enhancing the properties of constituent nanoparticles, such 
as achieving a stronger magnetic moment while preserving superparamagnetic properties, 
but also takes advantage of the interactions between individual nanoparticles which 
creates new characteristics absent from the constituent nanoparticles, such as strong 
optical absorbance in the NIR window. Furthermore, we also developed an antibody 
conjugation procedure to the hybrid nanoparticles for various biomedical applications 
which require molecular specific targeting. Antibodies are attached through the Fc moiety 
leaving the Fab portion that is responsible for antigen binding available for targeting. The 
contents of this chapter have been published in the journal ACS Nano8, accepted in 
Journal of Visualized Experiments and Advanced Functional Materials. 
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Figure 2.1 Synthetic scheme of magneto-plasmonic nanoparticles.   
2.2 PRIMARY AU SHELL/FE3O4 CORE NANOPARTICLES 
2.2.1 Materials and Methods 
Synthesis and characterization of gold shell/iron oxide core nanoparticles 
The gold-coated iron oxide nanoparticles were prepared according to a previously 
published protocol with a number of modifications.17 Briefly, 1 mM iron(III) 
acetylacetonate was mixed in 10 mL phenyl ether, followed by adding 3 mM oleic acid, 2 
mM oleylamine, and 3 mM 1,2-hexadecanediol (Fisher Scientific). The mixture was 
stirred vigorously, heated to 260 °C, and refluxed for 1 h yielding a suspension of highly 
uniform 5.1 nm Fe3O4 nanoparticles. Five mL of the Fe3O4 nanoparticle suspension was 
cooled to room temperature followed by addition of 1.1 mM gold acetate, 0.75 mM oleic 
acid, 3 mM oleylamine, 3 mM 1,2-hexadecanediol, and 15 mL phenyl ether (Fisher 
Scientific) under vigorous stirring. The reaction mixture was heated to 180 °C and was 
refluxed for 1 h. Then, a dark purple precipitate was formed after addition of ethanol and 
centrifugation. The recovered gold-coated iron oxide nanoparticles were dispersed in 
hexane. To render gold-coated iron oxide nanoparticles hydrophilic, the transfer of the 
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nanoparticles from organic to aqueous phase was modified as previously described.18 
Nanoparticles in hexane at ca. 0.6 mg nanoparticle/mL and equal volume of 5 mM α-
cyclodextrin (α-CD, Fisher Scientific) were mixed and stirred overnight at room 
temperature. Then, the nanoparticles were recovered by centrifugation, and the 
supernatant was discarded. The precipitate was resuspended in 0.2 mM sodium citrate 
using 10 min sonication.   
Transmission election microscopy (TEM) images were obtained using a FEI 
TECNAI G2 F20 X-TWIN TEM at 80 keV. The samples were prepared by depositing 10 
μL of a nanoparticle suspension onto a carbon-coated copper TEM grid for observation. 
UV-Vis spectra were collected with a BioTek Synergy HT micro-titer plate spectrometer. 
Magnetic properties of the core/shell nanoparticles were characterized using SQUID 
magnetometry upon cycling the field between ­50 K Oe to 50 K Oe at 300 k. 
Conjugation of monoclonal antibodies to nanoparticles 
Anti-Epithelial Cell Adhesion Molecule (EpCAM), anti-HER2, anti-EGFR, and 
anti-Cytokeratin (CK) antibodies (Sigma Aldrich) were attached to the gold 
shell/magnetic core nanoparticles via a heterofunctional PEG linker with hydrazide and 
dithiol moieties - dithiolaromatic PEG6-CONHNH2 (SensoPath Technologies). Antibody 
solution (100 μL, 1 mg/mL) in 4 mM HEPES was incubated in the dark with 10 μL 100 
mM NaIO4 for 30 min at room temperature, followed by quenching the reaction with 500 
μL phosphate buffered saline (PBS). Then, 2 μL of 46.5 mM linker solution was added to 
the antibody solution and shaken gently for 1 h. The excess linker was removed by 
filtration in a 10,000 MWCO centrifuge filter (Millipore) at 2,000g, 8 °C for 16 min. The 
retained antibodies were resuspended in PBS to a concentration of 1 mg/mL. The 
modified antibodies were mixed with gold shell/magnetic core nanoparticles in 4 mM 
HEPES for 1 h at room temperature. Then, 10−5 M 10 kD PEG-thiol (SensoPath 
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Technologies) was added to passivate the remaining nanoparticles surface. The 
functionalized nanoparticles were recovered by centrifugation at 2,000g for 5 min and 
were resuspended in 2 % w/v 10 kD PEG in PBS. 
Cell labeling specificity assays 
COLO 205, SK-BR-3, and A-431 cells (ATCC) were used as cancer cell models 
to demonstrate molecular specific cellular imaging. Cells were cultured in Dulbecco's 
Modified Eagle Medium (DMEM, Life Technologies) supplemented with 5 % fetal 
bovine serum (FBS, Hyclone), and harvested at ~90% confluence with trypsin. Cell 
suspensions containing ~3×105 cells were resuspended in complete media. Then, 
approximately 6×1012 immunotargeted nanocarriers conjugated with either anti-HER2, 
anti-EGFR, or anti-EpCAM antibodies were added to a cell suspension for 2 h at room 
temperature under mild mixing. To target the intracellular cytokeratins, cells were fixed 
with 4% formaldehyde for 10 min followed by permeabilized with 1% Triton X-100 
(Sigma Aldrich) for 15 min before incubating with immunotargeted nanocarriers against 
anti-CK. After incubation with nanocarriers, cells were washed in PBS and were spun 
down to remove any unbound nanoparticles followed by imaging using 20×, 0.5-NA 
dark-field objective under Leica DM6000 upright microscope. 
2.2.2 Results and Discussion 
Gold shell/iron oxide core nanoparticles 
Parameters of an optimal immunomagnetic nanocarrier include monodispersity, 
high-stability in aqueous phase, and ease of conjugation with targeting antibodies. Here, 
highly uniform Au shell/Fe3O4 core nanoparticles were synthesized via thermal 
decomposition of iron(III) acetylacetonate in a mixture of oleylamine and oleic acid 
followed by reduction of gold acetate in the presence of the iron oxide seeds.17 TEM of 
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both Fe3O4 and Au shell/Fe3O4 core nanoparticles dispersed in organic solvent shows 
spherical, uniform nanocrystals (Figure 2.2a and 2.2b). The core/shell nanoparticles were 
transferred into aqueous phase by mixing the particles in hexane with alpha-cyclodextrin 
molecules dissolved in water. α-CD is cyclic oligosaccharides containing six 
glucopyranose units whose hydrophobic cavities can form complexes with organic 
molecules and hydroxyl groups on rims provide hydrophilic properties.18 Therefore, the 
interaction between α-CD and oleic acid on nanoparticle surface stabilizes nanoparticles 
during phase transfer. The α-CD modified core/shell nanoparticles were readily dispersed 
in water with no detectable aggregation (Figure 2.2c). The core/shell nanoparticles in 
water phase had a narrow size distribution with the mean diameter of 6.2 ± 0.8 nm that 
was determined from TEM measurements of more than 200 particles (Figure 2.2d). 
The uniform gold coating is evident from the darker appearance of the core/shell 
nanoparticles as compared to the Fe3O4 precursors in TEM images (Figure 2.2a and 2.2b). 
In addition, the UV-Vis absorption spectrum of Au shell/Fe3O4 core nanoparticles shows 
a distinctive absorption band at 533 nm that is associated with the surface plasmon 
resonance of the gold shell (Figure 2.2e); this plasmon resonance determines red color of 
the core/shell nanoparticle suspension. Size comparison of Fe3O4 and Fe3O4/Au core/shell 
nanoparticles using TEM images showed that the thickness of the gold layer is 
approximately 1.1 nm.  Magnetic properties of the core/shell nanoparticles were 
characterized using SQUID magnetometry upon cycling the field between ­50 K Oe to 50 
K Oe at 300 k. The maximum magnetization value is 16.13 emu/g, and neither coercivity 
nor remanence was observed indicating superparamagnetic property of the nanoparticles 
(Figure 2.2f). The nanoparticles can be quickly separated from a colloidal suspension 
using a magnetic field gradient created by a simple permanent magnet as can be seen in 
the insert in Figure 2.2f. 
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Figure 2.2 Characterization of magnetic core/shell nanocarriers. TEM images of Fe3O4 
nanoparticles in hexane before (A) and after (B) coating with gold shell; gold 
shell/magnetic core nanoparticles after transferring into aqueous phase (C). 
Gold shell/Fe3O4 core nanoparticle size distribution (6.2 ± 0.8 nm) as 
determined from TEM image analysis of more than 200 particles (D). UV-Vis 
spectrum of oleic acid and oleylamine stabilized Fe3O4 nanoparticles (dashed) 
and gold shell/magnetic core particles in hexane (solid) (E). Magnetization 
hysteresis at 300 K of gold shell/magnetic core nanoparticles (F); the insert: 
separation of nanoparticles from a colloidal suspension using a magnetic field 
gradient created by a simple permanent magnet.  
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Molecular targeted nanoparticles 
For molecular specific targeting of cancer biomarkers the core/shell nanoparticles 
were conjugated with monoclonal antibodies. Monoclonal antibodies are widely utilized 
probes due to their high binding constants and availability for a large number of 
established biomarkers.19 Our conjugation strategy relies on directional covalent 
attachment of antibodies to gold nanoparticles through Fc moiety with the antigen 
binding sites on the Fab portion directed outward from the gold surface, and therefore 
available for targeting.20, 21 The conjugation is carried out using a heterobifunctional PEG 
linker terminated at one end by a hydrazide moiety, and by a di-thiol group at the other 
end. First, the carbohydrate moiety on the antibody’ Fc region is oxidized to an aldehyde 
group using sodium periodate; thereby allowing for preferential oxidation of orthodiols 
through a dehydration reaction. Although tyrosine and serine amino acids contain 
hydroxyl groups, they are not on the nearest neighbor carbons and therefore cannot be 
oxidized by sodium periodate.22, 23 Then, the oxidized antibodies interact with hydrazide-
PEG-thiol linkers in a reaction where the hydrazide portion of the linker reacts with the 
aldehyde formed during the oxidation reaction of antibody carbohydrate to form a stable 
linkage (Figure 2.3). The linker modified antibodies interact with gold surface of 
core/shell nanoparticles through the linker’s thiol groups. Subsequently, methyl-PEG-
thiol molecules are added to passivate any remaining bare gold surfaces thereby 
increasing the biocompatibility and reducing potential nonspecific interactions 
(Figure 2.3). Attachment of antibodies through the Fc region can be expected to diminish 
non-specific interactions between nanoparticle conjugates and Fc receptors of blood cells 




Figure 2.3 Schematic of an antibody molecule modified using a hetero-functional linker 
(left) and an immunomagnetic nanocarrier (right).  
Molecular specificity of immunotargeted nanoparticles 
The molecular specificity was demonstrated in three cell lines with known 
phenotypes: (1) COLO 205 − a model of colorectal cancer which expresses a high level 
of epithelial cell adhesion molecules (EpCAM), is positive for cytokeratin (CK) 
expression and is negative for both epidermal growth factor receptor-2 (HER2) and 
epidermal growth factor receptor-1 (EGFR); (2) SK-BR-3 − a breast cancer model which 
is EpCAM+/HER2+/EGFR−/CK+; and (3) A-431 − a model of skin cancer with the 
following expression profile EpCAM+/HER2−/EGFR+/CK+.24, 25 Each cancer cell line 
was labeled with immunomagnetic nanocarriers targeted to either EpCAM, HER2, 
EGFR, or CK. The specificity of labeling was characterized by comparing the binding of 
the immunotargeted nanoparticles to cells with varying biomarker expression using dark-
field microscopy (Figure 2.4). 
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Figure 2.4 Dark-field reflectance images of cancer cells labeled with immunomagnetic 
nanocarriers. Columns correspond to cancer cells with the following 
expression profiles: COLO 205 (EpCAM+/HER2−/EGFR−/CK+), SK-BR-3 
(EpCAM+/HER2+/EGFR−/CK+), and A-431 
(EpCAM+/HER2−/EGFR+/CK+). Rows show labeling results obtained with 
(from top to bottom): anti-EpCAM, anti-HER2, anti-EGFR, anti-CK and no 
nanocarriers. The yellow-orange color in the darkfield images is associated 
with binding of the nanocarriers; unlabeled cells have a grey-bluish 
appearance.  
In dark-field images, a yellow-orange color indicates specific binding of the 
nanoparticles to cancer cells whereas a grey-bluish color corresponds to the endogenous 
scattering of unlabeled cells.26-30 As can be seen in Figure 2.4 the labeling pattern of 
cancer cells correlates very well with their known expression profiles demonstrating 
molecular specificity of the immunomagnetic nanocarriers. Indeed, all cells showed good 
 27 
labeling with anti-EpCAM nanoparticles while only HER2+ SK-BR-3 cells and EGFR+ 
A-431 cells were labeled with anti-HER2 and anti-EGFR nanoparticles, respectively. 
Unbound nanocarries can be seen in some of the images; this is due to residual 
nanoparticles after a washing step. In addition to labeling of cytoplasmic membrane 
proteins − HER2, EGFR and EpCAM, we also demonstrated successful targeting of 
cytokeratin that is an intracellular biomarker of epithelial cells (Figure 2.4). The 
intracellular labeling is facilitated by the small size of the immunomagnetic 
nanoparticles. In addition, the cells were permeabilized using a procedure that is common 
in immunostaining of intracellular proteins. The ultra-small immunotargeted 
nanoparticles permitted passage through the permeabilized cell membrane and specific 
interactions with intracellular molecules. The ability to target a variety of intracellular 
molecular biomarkers opens new opportunities for the capture of CTCs since prevalent 
and universal biomarkers inside the cells reduce the variability that results from the 
heterogeneous levels of surface antigen expression.24, 31 
2.3 SELF-ASSEMBLY HYBRID NANOCLUSTERS FROM PRIMARY NANOPARTICLES 
The 6 nm diameter core/shell nanoparticles have demonstrated versatility in 
labeling phenotypically different cancer cells, targeting both surface receptor molecules 
and intracellular biomarkers of epithelial-derived cancer cells. However, they also have 
identified limitations, such as a relatively small magnetic moment and exhibition of the 
plasmon resonance at ca. 520 nm where whole blood has a strong absorbance.8 The latter 
limitation is overcome when spherical plasmonic nanoparticles are targeted to an 
overexpressed cancer biomarker or when they undergo an endosomal uptake by cancer 
cells; in this case, the effect of plasmon resonance coupling between closely spaced 
nanoparticles results in a strong broadband absorbance that extends to the NIR. However, 
 28 
the effect of surface plasmon resonance coupling is not likely to be observed for all 
cancer biomarkers of interest. Here, we address these shortcomings by development of a 
new type of hybrid magneto-plasmonic nanostructures using oil-in-water microemulsion 
method.16, 32 The nanostructures are synthetized from hybrid primary 6 nm iron oxide 
core-gold shell nanoparticles which self-assemble in highly dense spherical nanoclusters. 
The use of hybrid primary particles ensures consistent ratio of magnetic (iron oxide) and 
plasmonic (gold) moieties of the resulting nanoclusters. The dense packing of hybrid 
primary particles does not change their superparamagnetic properties and, therefore, the 
overall magnetic moment of the nanoclusters is not limited by the size transition of iron 
oxide from superparamagnetism to ferrimagnetism. Furthermore, close packing of the 
primary particles also results in strong red-NIR plasmon resonances that are not present 
in the primary particles. 
2.3.1 Materials and Methods 
Synthesis and characterization of hybrid nanoclusters 
Oleic acid-capped Au shell/ iron oxide core primary nanoparticles were 
synthesized according to a previously published method.33 Briefly, 1 mmol iron(III) 
acetylacetonate was mixed in 10 mL of phenyl ether, followed by addition of 2 mmol 
oleic acid, 2 mmol oleylamine, and 5 mmol 1,2-hexadecanediol. The mixture was stirred 
and heated to 260 °˚C for 1 h under reflux. Then, 5 mL of as synthetized Fe3O4 
nanoparticles was mixed with 1.1 mmol gold acetate, 0.75 mmol oleic acid, 3 mmol 
oleylamine, 3 mmol 1,2-hexadecanediol, and 15 mL of phenyl ether under vigorous 
stirring. The reaction mixture was heated to 180°C for 1 h under reflux. A dark purple 
precipitate was formed after addition of ethanol and centrifugation. The synthesis resulted 
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in primary magneto-plasmonic particles with ca. 6 nm diameter that were dispersed in 
hexane.  
To make nanoclusters, one volume of a suspension of the primary particles (5 
mg/mL by total weight) in hexane was mixed with ten volumes of deionized water 
containing an anionic surfactant − sodium dodecyl sulfate (SDS, Sigma Aldrich) at 2.8 
mg/mL.16 The mixture was placed in a sonicator bath (Model 1510, Branson) for 2 h. 
After starting the sonication, the solution was shaken by hand gently to facilitate mixing 
between the phase containing primary hybrid nanoparticles and the bottom aqueous 
phase. The solution was heated in a water bath at 80 °C for 10 min to remove hexane. 
The synthetized nanoclusters at this point had a wide size distribution. Nanoclusters with 
various sizes were separated using the following sequence of centrifugation steps: first, 
nanoclusters with sizes ca. 180 nm were collected by centrifugation at 100 ×g for 30 min; 
then, ca. 130 nm size was separated from the residual suspension applying the force of 
400 ×g for 30 min; and ca. 90 nm size was recovered using 1500 ×g for 30 min. 
The size and morphology of nanoclusters were examined using a FEI TECNAI 
G2 F20 X-TWIN TEM at 80 keV, and FEI Quanta 650 SEM. Ultraviolet-visible-NIR 
(UV-Vis-NIR) absorbance spectra were collected with a BioTek Synergy HT micro-titer 
plate spectrophotometer. Magnetization curves were analyzed using SQUID 
magnetometry upon cycling the magnetic field from − 10 K Oe to 10 K Oe at 300 K. A 
DelsaNano (Beckman Coulter) was used to determine zeta potentials of the nanoparticles. 
The response of the bare particles to a magnetic field as a function of time was 
characterized by placing a cubic magnet (1 × 1 × 1 cm, NdFeB, K&J Magnetics) next to 
one side of a 1 cm cuvette loaded with nanoparticles, followed by measurements of UV-
Vis-NIR spectra from the colloidal suspension over time. 
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Conjugation of monoclonal antibodies to hybrid nanoclusters  
The carbohydrate moiety on the Fc portion of monoclonal IgG antibodies − anti-
Epidermal Growth Factor Receptor 2 (HER2) antibody (E2777, Sigma Aldrich) and anti-
Epidermal Growth Factor Receptor 1 (EGFR) antibody (E2156, Sigma Aldrich) − were 
thiolated following our previously published protocol.34 Briefly, 10 μL of 100 mM NaIO4 
was added to 100 μL of monoclonal antibody solution (1 mg/mL) in pH 7.2 HEPES for 
30 min under dark conditions. The reaction was quenched with 500 μL of 1x PBS. Then, 
2 μL of 46.5 mM heterobifunctional polyethylene glycol linker solution (dithiolaromatic 
PEG6-CONHNH2, SensoPath Inc.) was mixed with the antibody solution for 1 h at room 
temperature. The linker modified antibodies were purified using a 10k MWCO centrifuge 
filter at 3,250 ×g for 20 min at 8 °C. Then, the modified antibodies (1 μL at 1 mg/mL) 
were mixed with the nanoclusters (100 μL at O.D. 1) for 2 h at room temperature. 
Finally, 10 μL of 10−3 M 5 kDa methyl-PEG-SH (SensoPath Technologies) was added to 
the mixture to replace any residual SDS molecules from the surface of nanoclusters. The 
functionalized nanoclusters were recovered by centrifugation at 830 ×g for 3 min, and 
were resuspended in 100 uL 2 % w/v 5 kDa PEG in PBS. 
Cell labeling specificity assays 
Cancer cells SK-BR-3 and A-431 (ATCC) were cultured in Dulbecco's Modified 
Eagle Medium (DMEM, Gibco) supplemented with 5 % fetal bovine serum (FBS, 
Hyclone). Before labeling with nanoclusters, cells were harvested at ~90% confluence 
using trypsin and resuspended in 1 mL complete media containing ca. 5×105 cells. 
Nanoclusters (0.05 nM) conjugated with either anti-HER2 or anti-EGFR antibodies were 
mixed with a cell suspension for 2 h at room temperature under mild shaking. After 
incubation with nanoclusters, cells were washed from any unbound particles via 
centrifugation at 182 ×g for 3 min and were resuspended in a phosphate buffered saline. 
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Then, dark field images of the cells were obtained under Leica DM6000 upright 
microscope using 20×, 0.5-NA dark field objective and a Xe-lamp illumination. 
Hyperspectral images were acquired in bright-field transmittance mode under 
Leica DM600 upright microscope equipped with a PARISS spectral imager (Lightform) 
using a 20×, 0.5-NA objective and a 100 W halogen light source. The wavelength 
calibration was carried out using a standard low pressure Hg wavelength calibration lamp 
(Lightform). The hyperspectral images of cells were normalized by a spectrum obtained 
from a region without cells. 
Cell viability assay 
Three groups of A-431 cells (5×103 cells) were incubated with SDS-capped 
clusters, CTAB (Cetyltrimethylammonium Bromide)-capped clusters, and PEG-capped 
clusters (particle concentration − 0.05 nM, sterilized by passing through 0.45 μm filter) in 
a phenol-free DMEM cell culture media supplemented with 5% FBS for 8 hours at 37°C. 
The cells incubated with nanoclusters and the untreated cell control were then washed 
twice with PBS and mixed with 100 μL MTS reagent, a mixture of MTS (3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) 
(0.32 mg/mL, Promega) and PMS (phenazine methosulfate) (7.3 μg/mL, Sigma Aldrich) 
in cell culture media. Absorbance at 490 nm was taken 3 h after the addition of the MTS 
reagent using a BioTek Synergy HT micro-titer plate spectrophotometer; the absorbance 
is proportional to the number of metabolically active live cells in a sample. 
2.3.2 Results and Discussion 
Hybrid magneto-plasmonic nanoclusters 
Oil-in-water microemulsion has been demonstrated as a versatile method to 
prepare single material nanoclusters with high colloidal stability. Size, composition, and 
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surface charge of the nanoclusters are controllable and tunable by choosing primary metal 
nanoparticles and surfactants.32 Several types of nanoclusters have been successfully 
synthesized and characterized by using magnetic (Fe3O4), plasmonic (Au), or 
semiconductor (CdS) primary nanoparticles.16 Here, we extended this microemulsion 
approach to the synthesis of novel hybrid nanostructures with dual magneto-plasmonic 
properties (Figure 2.5). Nanocluster formation requires amphiphilic surfactants with a 
hydrophobic moiety to hold together the primary particles inside the cluster, through 
hydrophobic van der Waals interactions, and a polar group to provide aqueous solubility. 
There are many surfactants that can be used for this purpose such as cationic surfactants 
(e.g. cetyltrimethylammonium bromide (CTAB)), anionic surfactants (e.g. sodium 
dodecyl sulfate (SDS)), nonionic surfactants (e.g. Triton X-100), and polymers (e.g. 
polyethyleneimine). The surfactant choice depends on the application. In our case, we 
chose anionic SDS molecules because they result in nanoclusters with enhanced 
biocompatibility and can be easily replaced with methyl-PEG-thiol (mPEG-SH) 
molecules, as shown below. 
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Figure 2.5 The synthesis scheme of the magneto-plasmonic nanoclusters by utilizing an 
oil-in-water microemulsion method.   
Critical steps in successful synthesis of magneto–plasmonic nanoclusters include 
making highly monodispersed primary gold shell/iron oxide core nanoparticles and 
directing self-assembly of the primary particles into nanoclusters. A molar ratio between 
the primary particles and surfactants play an important role in determining size 
distribution of the nanoclusters. Non-uniform size distribution of primary nanoparticles 
may cause formation of big aggregates during assembly of magneto-plasmonic 
nanoclusters. In addition, the microemulsion method of nanocluster formation relies on 
amphiphilic surfactants: hydrophobic tail groups hold primary nanoparticles together and 
hydrophilic head groups stabilize nanoclusters in an aqueous solution. Concentration of 
surfactants determines nanocluster assembly: a high concentration would lead to 
formation of smaller nanoclusters or individual primary particles and a low concentration 
would result in particle aggregation. 
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First, primary iron oxide core/gold shell nanoparticles were prepared via the 
thermal decomposition method.35 The resultant oleic acid-capped core/shell nanoparticles 
show high monodispersity with a 6.2 ± 0.8 nm diameter and are readily dispersed in 
hexane (Figure 2.6A). In a typical nanocluster synthesis, a suspension of the core/shell 
primary nanoparticles in hexane were carefully added to an aqueous solution containing 
anionic SDS surfactants with a hexane-to-water ratio of 1:10 by volume. The 
nanoclusters are formed under ultrasound treatment at the interfacial layer between the 
two immiscible phases. During this process the amphiphilic SDS surfactants from the 
aqueous phase undergo hydrophobic van der Waals interactions with the hydrocarbon tail 
of oleic acids, which stabilize the primary nanoparticles in hexane. Meanwhile, the 
hydrophilic head groups of SDS molecules interact with the aqueous phase acting as 
stabilizing agents and preventing aggregation of the forming nanoclusters (Figure 2.5). 
Subsequent heating of the reaction mixture above the boiling temperature of hexane 
results in hexane evaporation, and final formation of magneto-plasmonic nanoclusters 
with densely packed primary particles (Figure 2.6B).  
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Figure 2.6 Characterization of magneto-plasmonic nanoclusters. (A) TEM image of 
primary gold shell/Fe3O4 core nanoparticles. (B - D) TEM image, SEM image 
and size distribution of ca. 180 nm diameter magneto-plasmonic nanoclusters, 
respectively; the size distribution was determined from TEM image analysis 
by counting more than 200 particles. (E and F) UV-Vis spectra of primary 
particles (dotted line) and nanoclusters (solid line) with the same mass of Au 
before and after normalization, respectively; the insert in (E) shows changes in 
colloid color from red for primary particles to purple-grey for nanoclusters.   
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Scanning electron microscopy (SEM) indicates that primary particles retain 
individual character and serve as building blocks in nanocluster formation (Figure 2.6C). 
As-synthesized nanoclusters have a wide size distribution from several nanometers to 
~300 nm that requires an additional separation step. Various size fractions were separated 
by a gradient centrifugation (Figure 2.7). Figure 2.6D shows size distribution of 
nanoclusters with sizes 180 ± 39 nm as determined from TEM measurements of about 
200 particles. Finer separation to produce narrower distributions should be possible by 
using a size-exclusion chromatography. This nanocluster size was selected, after 
thorough evaluation, because it exhibits significantly stronger NIR absorbance as 
compared to smaller nanoclusters (Figure 2.7). There are pronounced differences in the 
absorbance spectra of nanoclusters and primary nanoparticles (Figure 2.6E); the spectra 
were obtained for suspensions with the same mass of Au as determined by ICP-MS. 
Purple colloidal suspension of primary core/shell nanoparticles indicates a distinctive 
absorbance peak at 538 nm, which is characteristic of isolated core/shell spheres. The 
grey nanocluster dispersion has a broad absorbance in the NIR region (Figure 2.6F), 
which can be attributed to a plasmon resonance coupling between the closely spaced 
primary particles. The inter-particle gaps are a fraction of the primary particle diameter, 
thereby resulting in broadening and a red-NIR shift in the absorbance of the 
nanoclusters.16, 21, 36, 37 However, It is interesting to note that there is a gradual increase in 
the NIR absorbance with increase in nanocluster sizes (Figure 2.7). Previously, it has 
been shown that asymmetrical clusters made from ca. 5 nm diameter gold nanoparticles 
with sizes as small as ca. 25 nm have a strong and broad NIR absorbance.38 A 
pronounced increase in the NIR absorbance for the larger nanoclusters was associated 
with a significant difference in optical properties of primary particles that are located on 
the surface versus particles located in the inner nanocluster core, which becomes more 
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pronounced as size increases.39, 40 However, a thorough theoretical analysis would need to 
be carried out in order to get a better understanding of the optical behavior of these 
composite nanoclusters that is outside the scope of this study. 
 
 
Figure 2.7 Size selection of as-synthesized nanoclusters (90, 130, and 180 nm) and 
comparison of UV-Vis spectra of primary particles (6 nm) and nanoclusters 
with various sizes.   
 
Magnetic properties of nanoclusters were characterized using SQUID 
(superconducting quantum interference device) magnetometry by cycling the field 
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magnetic field between +10 and −10 K Oe at 300 K. Neither coercivity nor remanence 
was observed, indicating superparamagnetism with both the primary particles and the 
nanoclusters (Figure 2.8A). The nanoclusters and the primary particles exhibited similar 
magnetization, indicating that the constituent particles are separated inside the 
nanoclusters. The small ca. 1.85 emu/g increase in the magnetization of nanoclusters can 
be attributed to a cooperativity effect between closely spaced iron oxide cores.41 Because 
the magnetic moment of a superparamagnetic nanoparticle in an external magnetic field 
is proportional to nanoparticle’s volume, the nanoclusters exhibit greatly improved 
response to an external magnet (Figures 2.8B and 2.8C). A suspension of either primary 
particles or nanoclusters was placed next to a permanent magnet in a cuvette with a 1 cm 
pathlength, and the depletion of the nanoparticles from each dispersion was measured 
using UV-Vis spectrophotometry. The absorbance at time point zero (no magnet) at 590 
nm for nanoclusters and 538 nm for primary particles gave 100% of the total amount of 
nanoparticles. After 5 min magnetic incubation, the nanocluster solution was depleted 
53% versus a 7% for the primary particles (Figures 2.8B and 2.8C).  After 15 min 
incubation, 73% of nanoclusters and 16% of primary particles were captured by the 
magnet. Therefore, the use of nanoclusters results in a significantly increased magnetic 
force while preserving superparamagnetic properties of the nanoparticles. 
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Figure 2.8 Characterization of magnetic properties of nanoclusters. (A) Magnetization 
hysteresis at 300 K of primary particles and nanoclusters. (B, C) Efficiency of 
magnetic separation of nanoclusters (B) and primary particles (C) from a 
colloidal suspension in a 1 cm cuvette in the presence of a permanent magnet. 
The yield (%) represents the portion of nanoparticles attracted to the magnet 
after 15 min magnet incubation as determined by the following formula: (1 – 
([peak absorbance of magnet-treated sample]/[peak absorbance control sample 
without a magnet] )) × 100%. The photographs show changes in turbidity of 
colloidal suspensions over time.   
Biocompatibility of hybrid nanoclusters 
It has been shown that biocompatibility of plasmonic nanoparticles is highly 
dependent on their surface coating.42 Several strategies can be employed to ensure 
nanoparticle biocompatibility, including the use of biocompatible surfactants during 
particle synthesis or the conjugation of biocompatible molecules on nanostructures after 
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their synthesis. Here, we characterized the cellular toxicity of nanoclusters synthetized 
using CTAB and SDS capping ligands, as well as nanoclusters prepared by replacing 
SDS ligands with mPEG-SH molecules. Zeta potentials of the CTAB and SDS-capped 
nanoclusters were +48.5 ± 0.3 mV and −47.6 ± 6.0 mV, respectively (Figure 2.9). SDS 
replacement with mPEG-SH molecules results in a nearly neutral surface charge of +3.3 
± 2.6 mV, indicating successful ligand exchange. 
  
 
Figure 2.9 Zeta potential of nanoclusters with various surface coatings.   
 
Cell viability studies were performed using the A-431 cancer cell line (Figure 
2.10). Cell viability decreased by 80% and 65% after exposure to CTAB and SDS capped 
nanoclusters, respectively, while replacement of SDS with mPEG-SH molecules resulted 
in biocompatible nanoclusters which did not show any cytotoxic effects. These results are 
consistent with previous reports where CTAB coated nanoparticles exhibited high 
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cytotoxity.43 Similarly, SDS molecules are widely used to linearize proteins in SDS-
PAGE (sodium dodecyl sulfate polyacrylamide gel electrophoresis) and, therefore, can 
adversely affect the function of many proteins.44 These results indicate that SDS is a 
preferable agent for nanocluster synthesis as it has a better biocompatibility when 
compared with CTAB. However, a ligand exchange of SDS with mPEG-SH is required 
in order to render biocompatible nanoclusters. 
  
 
Figure 2.10 Cytotxicity of nanoclusters coated with CTAB, SDS, or methyl-PEG-thiol 








Molecular targeted hybrid nanoclusters 
 
 
Figure 2.11 Schematic of the antibody conjugation to the nanoclusters through the 
antibody's Fc moiety using a hetero-functional linker.   
Nanoclusters were conjugated with monoclonal antibodies for molecular specific 
targeting of cancer cells. We used a directional covalent attachment of antibodies to the 
gold surface of the nanoclusters, leaving antigen binding sites on the Fab antibody region 
directed outward from the surface and therefore available for targeting.34 Briefly, a 
carbohydrate moiety on Fc antibody portion was first oxidized to an aldehyde group 
using sodium periodate. Then a heterobifunctional polyethylene glycol linker, terminated 
at one end by a hydrazide moiety and di-thiol group at the other end, was attached to the 
oxidized carbohydrates on the antibody via its hydrazide portion, which resulted in a 
stable hydrazone bond with aldehydes. The modified antibodies were attached to the 
nanoclusters through the di-thiol portion of the linker. Subsequently, mPEG-SH 
molecules were added to passivate the rest of the exposed surface to ensure 
biocompatibility of the molecular targeted nanoclusters (Figure 2.11). A red shift of ca. 
32 nm of the absorbance peak of the nanoclusters were observed after the antibody 
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conjugation, which indicates an increase in the local dielectric constant and, therefore, 
successful protein conjugation on the surface of nanoclusters (Figure 2.12).34 
Furthermore, the attachment of clone 225 monoclonal EGFR antibodies resulted in a 
negative zeta potential of −7.0 ± 1.4 mV (Figure 2.9); a similar trend was previously 
reported for gold nanoparticles conjugated with antibodies.43 The hydrodynamic radius of 
nanoclusters increases ~10 to 15 nm after antibody conjugation. This increase in diameter 
correlates well with ca. 12 nm size of an IgG antibody that is attached through the Fc 
moiety to the surface of nanoparticles. Therefore, the change in the hydrodynamic 
diameter is consistent with the directional conjugation chemistry for antibody attachment 
through the Fc portion.  
 
Figure 2.12 UV-Vis spectra of 180 nm diameter nanoclusters (red) and the nanoclusters 
conjugated with anti-EGFR antibodies (blue). Note a red shift in the 
absorbance of the functionalized nanoclusters.   
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Molecular specificity of immunotargeted nanoclusters 
Molecular specificity of targeted nanoclusters was tested in two cell lines: (1) A-
431 keratinocytes which express a high level of EGFR and are negative for epidermal 
growth factor receptor-2 (HER2), and (2) SK-BR-3 breast cancer cells which are negative 
for EGFR expression and positive for HER2. Nanoclusters targeted to either EGFR or 
HER2 and non-targeted PEGylated clusters were incubated with both cell types (Figure 
2.13). Dark-field microscopy images illustrated a bright orange color that is associated 
with light scattering from the nanoclusters for both the A-431 and SK-BR-3 cells 
incubated with EGFR and HER2 targeted nanoclusters, respectively. In contrast, cells 
exhibited characteristic bluish-grey color due to intrinsic cellular scattering after 
incubation with either targeted nanoparticles that did not match their expression profile or 
with PEGylated nanoclusters. Therefore, these results demonstrate molecular specificity 




Figure 2.13 Dark-field reflectance images of cancer cells labeled with nanoclusters. Rows 
correspond to cancer cell with the following expression profiles: A-
431(EGFR+/HER2−) and SK-BR-3 (EGFR−/HER2+). Columns show 
labeling results obtained with nanoclusters conjugated with anti-EGFR 
antibodies, anti-HER2 antibodies or PEG molecules. The yellow-orange 
color in the darkfield images is associated with nanocluster binding; 
unlabeled cells have a characteristic grey-bluish appearance.   
Optical properties of particle-labeled cells 
We compared the optical properties of cells labeled with either primary particles 
or nanoclusters, which were both targeted to EGFR molecules (Figure 2.14).  The same 
mass of gold was used for each nanoparticle type in cell labeling experiments. Labeling 
with EGFR-targeted nanoclusters resulted in a greatly increased absorbance of the A-431 
cells when compared with anti-EGFR primary particles (Figure 2.14A). This data 
demonstrates the advantage of using bigger nanoparticles with higher absorbances for 
molecular specific cellular imaging; this is not necessarily a trivial result as the use of a 
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bigger particle could result in a steric hindrance in labeling of closely spaced 
overexpressed molecules. Normalized absorbance spectra indicated significant 
broadening and an increase in the red-NIR spectral region of nanoparticles that are 
interacting with cells, compared with isolated particles in a suspension (Figure 2.14B). 
These spectral changes can be attributed to the surface plasmon resonance coupling 
between nanoparticles which are brought in close proximity through their interactions 
with cellular EGFR receptors; this effect has been previously observed and characterized 
by our group.39, 45, 46 Optical imaging of single labeled cells confirms the results obtained 
using spectrophotometry of cell suspensions (Figure 2.14C-E). Both the bright-field and 
the dark-field imaging modalities show stronger contrast in the case of nanocluster 
labeled A-431 cells. Also, hyperspectral bright-field imaging revealed a much stronger 
absorbance in the red-NIR region of nanocluster labeled cells, compared with cells 







Figure 2.14 Optical properties of cells labeled with molecular targeted nanoparticles. (A, 
B) UV-Vis spectra of A-431 cells labeled with either EGFR-targeted primary 
particles or nanoclusters using the same mass of Au: (A) raw spectra, and (B) 
absorbance spectra of the labeled cells normalized to one after subtraction of 
the cell only spectrum in comparison with spectra from nanoparticle 
suspensions. (C – E) Optical properties of individual A-431 cells labeled 
with EGFR-targeted nanoclusters (C) or primary particles (D). The unlabeled 
cells are shown as a control (E). Columns from left to right: bright field (BF); 
dark field (DF); and hyperspectral absorbance (HS) images. The color bars 
show relative intensity distribution in the HS images for an integrated 
absorbance from 500 to 700 nm. Representative spectra at the right-hand side 
are obtained by integrating absorbance in the regions of interest highlighted 
by white boxes.   
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2.4 CONCLUSIONS 
Here, we created an immunotargeted magneto-plasmonic nanoparticle platform 
with the size range of 6 nm to 180 nm. The unique feature of our method is synthesis of 
magneto-plasmonic nanoparticles of various sizes from primary blocks which also have 
magneto-plasmonic characteristics. This approach yields nanoparticles with a high 
density of magnetic and plasmonic functionalities which are uniformly distributed 
throughout the nanoparticle volume. Our method is essentially a simple one-pot reaction 
after primary particles are synthesized. The overall plasmon resonance strength and 
magnetic moment are determined by the number of primary particles and, therefore, can 
be easily optimized depending on an application. We also demonstrated that the choice of 
the right surfactant in synthesis of the magneto-plasmonic nanoclusters and subsequent 
surface modification with PEG molecules are both important steps in producing 
biocompatible nanoclusters, which do not exhibit cytotoxic properties. The nanoclusters 
show a greatly improved response to an external magnetic field when compared with the 
constituent primary particles. In addition, the nanoclusters also have a strong NIR 
absorbance that is absent in the primary particles. The hybrid nanoparticles can be easily 
functionalized by attaching monoclonal antibodies through the Fc moiety leaving the Fab 
portion that is responsible for antigen binding available for targeting both surface 
receptor molecules and intracellular biomarkers. Therefore, this biocompatible magneto-
plasmonic nanoparticle platform exhibits the combination of properties which allow 
transition from highly promising feasibility studies to actual translation of magneto-
plasmonic nanoparticles to a variety of biomedical applications, including multi-modal 
molecular imaging, cell tracking, highly efficient assays for simultaneous capture and 
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Chapter 3: Development of Circulating Tumor Cell Detection Assays  
3.1 INTRODUCTION 
Detection of disseminated tumor cells or tumor biomarkers in human fluids such 
as blood, urine, and saliva can provide an opportunity to develop an accessible tool for 
cancer detection and monitoring.1-3 In particular, accurate quantitation of cancer cells in 
the bloodstream helps determine prognosis and monitor the effectiveness of cancer 
therapy.4-6 However, the challenge of detecting circulating tumor cells is their rare 
occurrence, estimated as one to few CTCs among millions of leukocytes and billions of 
erythrocytes. 
Immunomagnetic-capture technology is one of the most popular and effective 
approaches to detect CTCs. Most blood cells are with very weak magnetic properties7; 
hence, selective enhancement on CTCs by targeting them with magnetic substances can 
help effectively isolate CTCs from the blood. Magnetic materials can be modified with 
specific antibody to tag CTCs. After mixing functionalized magnetic materials with blood 
for a defined time, the sample is incubated with a non-uniform magnetic field. The 
labeled cells migrate toward the region with stronger magnetic field where they are 
captured. Immunomagnetic methods usually yield viable cells with unaltered biological 
information which aid further gene expression analysis. 
Several immunomagnetic-based capture assays have been introduced to detect 
and to count CTCs8, 9 and they all rely on one common biomarker − epithelial cell surface 
marker (EpCAM) - expression on disseminated tumor cells. The single approved system, 
CellSearchTM (Veridex), utilizes ferrofluids conjugated with anti-EpCAM antibodies to 
immunomagnetically enrich CTCs that express EpCAM.8 However, due to tumor 
heterogeneity and epithelial to mesenchymal transition (EMT), subpopulations of 
metastatic tumor cells do not often express this specific epithelial surface antigen or 
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express it at very low levels,10, 11 thereby limiting the value of EpCAM based assays for 
CTC detection. Thus, EpCAM-dependent assays have limited capability to detect CTCs 
from “normal-like” subtype of breast cancers which lack such expression.11, 12 
Furthermore, in a recent prospective multicenter clinical study, CTCs were detected in 
only 61% of metastatic breast cancer patients.4 Consequently, new approaches are 
required for an effective, highly sensitive, and specific detection of CTCs in whole blood. 
Our hypothesis is that a versatile platform that can target multiple clinical relevant cancer 
biomarkers may significantly improve CTC capture and, thus, provide a more accurate 
determination of the CTCs prevalence in cancer patients. 
A key component of our approach to a versatile CTC assay is built around recent 
progress in development of core-shell nanostructures which have been used in a wide 
range of applications such as drug delivery, imaging and cellular trafficking.13-16 Notably, 
bimetallic nanoparticles containing a magnetic core and a plasmonic gold shell enable 
novel imaging approaches and photothermal therapy.17-19 Furthermore, the gold shell 
facilitates conjugation of biological molecules to the nanoparticle surface for molecular 
targeting. Previously, we introduced directional antibody conjugation method through the 
Fc portion that leaves the antigen binding sites on the Fab moiety available for targeting; 
this approach improves molecular specificity of the conjugates.20, 21 In addition, 
nanoparticles with relatively small diameters (less than 10 nm) provide a number of 
unique advantages in molecular targeting such as reducing non-specific interactions, 
minimizing possible steric hindrance and increasing permeability in a biological 
environment such as cells and tissues.22, 23 
We described a CTC assay in Chapter 3.2 that is based on advances in the 
synthesis of immunotargeted magneto-plasmonic nanocarriers in combination with a 
microfluidic device (Figure 3.1). The nanocarriers are based on 6 nm gold shell/iron 
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oxide core nanoparticles conjugated with monoclonal antibodies that are specific to 
common biomarkers of CTCs. The very thin gold shell of ca. 1 nm provides a convenient 
surface for antibody conjugation and the magnetic core is used for efficient magnetic 
force separation of the labeled cancer cells from normal cells in whole blood. The 
versatility of the nanoparticle platform for detection and enumeration of rare cells was 
demonstrated in capturing experiments of phenotypically different cancer cells including 
breast, colon and skin cancers. Furthermore, from the previous chapter we have observed 
the target-mediated aggregation of nanoparticles when hybrid magneto-plasmonic 
nanoclusters interacted with cancer cells, resulting in a red spectral shift and broadening 
of the absorbance spectra in red to near-infrared region. This effect is based on the 
phenomenon of plasmon resonance coupling between closely spaced noble metal 
nanoparticles. Thus, we took advantage of this property to explore the feasibility of 
photoacoustic (PA) detection of labeled cancer cells. The assay based on a simultaneous 
magnetic capture and PA detection of CTCs was described in Chapter 3.3. The contents 
of this chapter have been published in the journal ACS Nano24, accepted in Advanced 
Functional Materials, and proposed to submit to Nanomedicine. 
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Figure 3.1 Conceptual cartoon of the versatile immunomagnetic nanocarrier platform in 
microfluidics for capturing circulating tumor cells in whole blood.   
3.2 MICROFLUIDIC DEVICE-BASED IMMUNOMAGNETIC DETECTION OF CIRCULATING 
TUMOR CELLS 
3.2.1 Materials and Methods 
Microchannel design 
To screen blood samples, we used polydimethylsiloxane (PDMS)-based 
microchannel combined with magnetic field gradient generated by arrayed magnets with 
alternate polarities.25 The microchannel with the height of 500 µm was fabricated through 
soft lithography using PDMS (Sylgard 184, Dow Corning, Midland, MI, 10:1 prepolymer 
to curing agent), with subsequent steps of bonding the PDMS channel with a glass 
coverslip (24 × 40 × 0.15 mm, Fisher Scientific).9 Dimensions of the microchannel are 
shown in Figure 5a. The inlet of the microchannel was connected to a reservoir for 
sample loading and the outlet was connected to a syringe pump (Harvard Apparatus) to 
control flow rates.  
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Whole blood samples spiked with cancer cells  
Blood samples from a healthy donor were spiked with a known number of cancer 
cells to determine sensitivity of the immunomagnetic nanocarrier platform. Whole blood 
samples were collected with CellSave tubes (Veridex). Three cell lines - COLO 205, SK-
BR-3, and A-431 - with known phenotypes were harvested, centrifuged, and resuspended 
in phosphate buffered saline. Ten µL cell suspension at a concentration of approximately 
20,000 cells per mL was added to a conical CellSave tube containing 2.5 mL of whole 
blood. The same amount of cell suspension was distributed on three glass slides to 
calculate the mean of cells spiked into the blood sample.  
Immunotargeted nanoparticle preparation  
A suspension of functionalized nanocarriers (100 µL, 50 nM) conjugated with 
either anti-EpCAM, anti-HER2, or anti-EGFR antibodies was added to the blood samples 
spiked with COLO 205, SK-BR-3, and A-431 cells, respectively. In addition, a 
combination of anti-EGFR and anti-EpCAM nanoparticles was used in capture 
experiments with A-431 cells and a combination of anti-HER2 and anti-EpCAM 
nanoparticles was applied for detection of SK-BR-3 cells. Each nanocarrier in the 
combinations was administered with equal volume (100 µL) and concentration (50 nM). 
BT-20 (ATCC) breast cancer cell line was used as a model of cells with a low EpCAM 
expression; this cell line was labeled with both anti-EpCAM nanocarriers and a 
combination of anti-EpCAM and anti-MUC1 nanocarriers. 
The labeling with anti-CK nanoparticles targeting the intracellular cytokeratin 
biomarkers required a cell fixation/permeabilization step before addition of the 
nanoparticles. The whole blood samples containing cancer cells were incubated with 4% 
formaldehyde for 10 min at room temperature. Then, 1% Triton X-100 was added to the 
solution for 15 min followed by two washing steps in PBS. 
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Screening procedures and analysis of whole blood samples  
The whole blood samples with spiked cancer cells and immunotargeted 
nanocarriers were incubated for 2 h under gentle shaking. Then, cancer cells were 
separated from the whole blood in the microfluidic chip described above that was 
operating at a continuous flow rate of 2.5 mL per hour. After the separation step, the 
microchannel was flushed with 3 to 4 mL of phosphate buffered saline to wash blood 
cells. Subsequently, 1 mL of ice-cold acetone was administered to the microchannel to 
fix captured cancer cells.  The slides were stained using nuclear dye 4’,6-diamidino-2-
phenylindole (DAPI, Vector Laboratories), anti-cytokeratin pan-FITC (Sigma Aldrich), 
and the anti-CD45 antibodies labeled with Alexa Fluor 568 (Invitrogen). Captured cancer 
cells were defined as DAPI+/CK+/CD45−, and white blood cells were classified as 
DAPI+/CK−/CD45+. The capture yield was calculated by dividing the number of cells 
found in the sample by the mean number of spiked cells.  
To determine dependence of capture efficiency on the number of cancer cells in 
whole blood, we conducted a series of experiments with a number of spiked COLO 205 
cells ranging from 5 to 500 in 2.5 mL of whole blood. Anti-EpCAM nanocarriers were 
used for cell capture and the experiments were carried out as described above. 
3.2.2 Results and Discussion 
Detection of spiked cancer cells in whole blood 
The efficiency of the immunomagnetic nanocarriers for the capture of cancer cells 
was examined with a microfluidic magnetic chip that we previously developed (Figure 
3.2A).9 In this device, a magnetic field gradient is generated by a permanent magnet that 
is placed on top of a 20 × 30 × 0.5 mm microfluidic chamber.9 In an example, shown in 
Figure 3.2, 2.5 milliliters of whole blood from a normal volunteer was spiked with ~100-
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200 COLO 205 cells and anti-EpCAM magnetic nanoparticles were added to label the 
cells. Then, the sample was passed through the microfluidic chamber at a continuous rate 
of 2.5 mL/h using a syringe pump. No additional purification or isolation steps were 
carried out prior to introduction of the blood sample to the chamber. 
 
 
Figure 3.2 Design of a microfluidic channel for immunomagnetic capture, detection and 
characterization of CTCs (A). An example of distribution of captured COLO 
205 cancer cells targeted with anti-EpCAM nanocarriers (B). Fluorescence 
and darkfield images of a captured COLO 205 cell (DAPI+/CK+/CD45−) and 
a white blood cell (DAPI+/CK−/CD45+); the cells were labeled using 
cytokeratin (CK), CD45 and DAPI stains (C).    
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The captured cancer cells were identified using fluorescent staining which allows 
distinguishing cancer cells with the epithelial tissue phenotype from the much larger 
population of nucleated white blood cells. The staining scheme that has been widely used 
in CTCs capture and enumeration experiments includes anti-CK, anti-CD45 and DAPI 
stains which are specific for epithelial cells, white blood cells and all nucleated cells, 
respectively.4 Figure 3.2C shows an example of staining results for a captured cancer cell 
and a white blood cell where cancer cells can be easily identified by the positive CK and 
negative CD-45 staining, while white blood cells are CK negative and CD45 positive.  
Most of the captured cancer cells were found where the first maximal magnetic 
field gradient exists (Figure 3.2B).25 For this design, these capture sites were located 
around 10 mm away from the inlet of the microfluidic chamber. Cancer cells with less 
nanoparticle loading travelled a longer path in the microchamber and were captured at 
regions farther away from the inlet. In this assay, coordinates of captured cancer cells can 
be recorded to facilitate subsequent specific molecular characterization analyses such as 
fluorescence in situ hybridization (FISH) or hyperspectral microscopic imaging (HMI) 
which can identify and select a broad spectrum of molecular moieties for better 
delineation of the true status of the captured cells. No false positive cells were observed 
in experiments with normal blood without spiked cancer cells.     
Capture efficiency  
The combination of the microfluidic magnetic chip and the immunomagnetic 
nanocarriers provides flexibility in capturing rare cancer cells using different extracellular 
and intracellular biomarkers with high capturing efficiency (Figure 3.3). To demonstrate 
this concept, we carried out a series of spiked experiments in the whole blood where A-
431 skin cancer cells, SK-BR-3 breast cancer cells and COLO 205 colon cancer cells 
were captured using cytoplasmic membrane protein targeted nanocarriers − anti-EGFR, 
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anti-HER2 and anti-EpCAM, respectively, according to an expression profile of each cell 
type (Figure 3.3A). In addition, the COLO 205 cells were also captured using 
nanocarriers targeted to the intracellular biomarker – cytokeratin. Notably, the capture 
efficiency exhibited by the cytokeratin targeting nanocarrier is the same as the 
efficiencies of the nanocarriers targeting cell surface proteins. The capture yield was 
70−80% in cases where a single nanocarrier was used that is comparable to the FDA-
approved CellSearchTM system and the recently described microchip system with 
antibody-coated microposts.8, 26 
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Figure 3.3 Cancer cell capture and enumeration. (A) Capture efficiency in spike 
experiments in 2.5 mL whole blood samples from a normal volunteer where 
COLO 205 (colon), SK-BR-3 (breast), A-431 (skin) or BT-20 (breast) cells 
were captured using immunomagnetic nanocarriers targeted to cancer 
biomarkers which are listed in the parentheses; each experiment was repeated 
at least 3 times. Note a significant increase (*p < 0.05) in the capture 
efficiency when a combination of nanocarriers is used for detection of A431, 
SK-BR-3 and BT-20 cells; this increase is especially pronounced in the case 
of a low EpCAM expressing BT-20 cells. (B) Number of captured cells as a 
function of spiked COLO 205 cells in 2.5 mL whole blood samples; the 
number of spiked cells was varied from 5 to 500 cells.    
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However, our approach to CTC assay allows straightforward multiplexing of 
immunotargeted nanocarriers to various cancer cell antigens, thereby increasing CTC 
detection.27 For example, using anti-EGFR and anti-EpCAM nanocarriers simultaneously 
for detection of A-431 cells increases the capture yield from 79% in the case of anti-
EGFR nanoparticles alone to 93% for the combination, similarly combining anti-HER2 
and anti-EpCAM nanoparticles improves the capture yield of SK-BR-3 cells from 69% 
obtained in the case of HER2 targeting alone to 93% for the combination (Figure 3.3A).  
We also explored the concept of using multiple nanocarriers to improve capture in 
cancers which express EpCAM antigen poorly or not at all. First, we manually 
reproduced CellSearchTM capture assay in spiked experiments in whole blood using the 
basal-like subtype of breast cancer cell line, BT-20, which expresses relative low 
EpCAM; the assay showed the capture efficiency of only ca. 44%. The same recovery 
rate was obtained using our anti-EpCAM immunomagnetic nanocarriers (Figure 3.3A). 
However, combining anti-EpCAM and anti-MUC1 nanocarriers together improved the 
capture efficiency from 45% to 78%. The nanocarriers in the combination were applied in 
1:1 ratio and the concentration of each nanoparticle was the same as in experiments with 
a single nanocarrier.  
Thus, utilizing multiple nanocarriers opens the route to significantly improve 
capture of CTCs with various expression profiles including capture of cancer cells that 
express EpCAM weakly on their surface.4 We also demonstrated that cell capture 
efficiency exhibits a linear behavior (the R2 value for the linear regression fit is 0.988) in 
spiking experiments with a number of COLO 205 colon cancer cells ranging from 5 to 
500 in whole blood (Figure 3.3B). For the group with only 5 cells, the capture yield was 
86%, whereas an average ca. 77% capture yield was obtained from the linear graph 
shown on Figure 3.3B. 
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In addition to the multiplexing capabilities demonstrated above, the advantages of 
our platform include the use of whole blood in CTC detection that eliminates multiple 
pre-processing steps including plasma replacement, centrifugation and sample transfer 
between tubes which are commonly used in other assays such as CellSearchTM. We also 
demonstrated the possibility of fluorescent staining inside the microfluidic chamber 
following cell capture. This in-channel procedure provides an efficient washing and 
fluorescent labeling due to short diffusion distances thus saving the amount of fluorescent 
reagents used, improving uniformity of staining and eliminating potential loss of captured 
cells. The CTC observation can be easily automated and individual cells can be analyzed 
using HMI to explore a large number of molecular markers for better delineation of the 
status of the captured cells. 
3.3 SIZE-SELECTIVE APPROACH WITH PHOTOACOUSTIC DETECTION OF CIRCULATING 
TUMOR CELLS 
3.3.1 Materials and Methods 
Photoacoustic imaging of nanocluster-labeled cells in tissue mimicking phantoms  
Photoacoustic imaging experiments were carried out using tissue-mimicking 
ultrasonic phantoms.28 First, a 5 cm thick base-layer was prepared using 8% gelatin, 
0.25% 40-μm silica particles, and 0.1% formaldehyde.29 Then, cell inclusions were made 
by mixing 7.5 μL of gelatin (16% gelatin, 0.5% 40-μm silica particles, and 0.2% 
formaldehyde) with 7.5 μL of formalin fixed pre-labeled A-431 cells. The inclusions 
contained ca. 105 cells and were pipetted onto the surface of the base-layer. After curing 
for 1 h at 4°C, the same procedure used to make the base layer was utilized to make a 1 
cm thick layer on top of cell inclusions.  
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Cell phantoms were imaged using a Vevo 2100 (VisualSonics) for the 
photoacoustic signal acquisition and a Quanta-Ray PRO-290 pumping a premiScan/MB 
tunable OPO (Spectra-Physics Lasers) for the photoacoustic excitation. For photoacoustic 
images acquired using wavelengths shorter than 710 nm, the laser beam from the signal 
port of the OPO was coupled into an Optran WF multimode optical fiber (CeramOptec 
Industries, Inc.). The diameter of the laser spot on the surface of the phantom was 1 cm 
and the fluence was maintained at 3 mJ/cm2 for all wavelengths using an array of neutral 
density (ND) filters. The 21 MHz transducer of the Vevo 2100 was positioned orthogonal 
to the surface of the phantom and was used to acquire the photoacoustic signals resulting 
from the nanosecond laser pulses. Photoacoustic images were acquired at 600 nm, 
650 nm, and 700 nm with the optical fiber and ultrasound transducer being stationary and 
the phantom moving so that a single inclusion with either labeled or unlabeled A-431 
cells was in the imaging plane. After the photoacoustic images were acquired, the laser 
source was switched from the signal port to the idler port of the OPO. The phantom was 
repositioned and photoacoustic images were acquired at 750 nm, 800 nm, 850 nm, 
900 nm, 950 nm, and 1064 nm wavelengths. An average of 50 photoacoustic images 
were obtained at each wavelength. The photoacoustic signal intensity from a small region 
of interest (3 × 3 mm) in the phantom was averaged and plotted as a function of 
wavelength. 
Magnetic capture efficiency test  
A-431 cells in culture medium (5×105 cells) were labeled with either anti-EGFR 
conjugated primary particles or nanoclusters (both at concentration of 0.05 nM) for 1 h at 
room temperature. After labeling, A-431 cells were washed with 1x PBS. The labeled 
cells were then resuspended in 1 mL of 1x PBS and placed into a 1 cm cuvette. A cubic 
magnet (1 × 1 × 1 cm, NdFeB, K&J Magnetics) was positioned next to the cuvette’s wall, 
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and a 10 μL sample was taken from the center of the cuvette at time points 5 min, 10 min, 
and 15 min. 
CTC assay setup and photoacoustic detection 
The whole blood samples (1 mL) with spiked A-431 cancer cells (1×103) and anti-
EGFR conjugated nanoclusters (100 μl, 50 nM) were incubated for 1 h at room 
temperature under mild gentle shaking. Then, the labeled cell solution was transferred to 
a cell culture insert which contains polyethylene terephthalate membrane filter with 8 μm 
pore (Falcon, BD). The insert was placed in a 6-well plate and the well was then filled 
with 1 mL PBS (Figure 3.4A). A 0.5 T neodymium magnet (K&J Magnetics) was placed 
under the well and the entire setup was gently shaken for 30 min. The insert was gently 
washed three times with 1 mL PBS in the presence of the magnet and subsequently 
immersed in ice-cold acetone for 10 min to fix the cells on the membrane. The porous 
membrane was then carefully cut from the insert and placed on a glass microscope slide. 
A 50 μm diameter stainless steel wire was placed on the membrane as an optical and PA 
image co-registration marker. The membrane and wire marker was mounted with 
fluoromount (Sigma Aldrich) and covered with a glass coverslip for imaging (Figure 




Figure 3.4 Schematic of the capture and enumeration of CTCs using a porous membrane 
and immunotageted hybrid nanoclusters. (A) Side-view of the magnetic 
enrichment setup. (B) Mechanism of magnetic capture where nanocluster-
labeled cancer cells were attracted and captured by the magnet on a porous 
membrane whereas unbound free nanoclusters and blood cells were filtered 
through the pores. (C) Sample preparation for photoacoustic imaging with a 
wire marker on the cell-loaded porous membrane for co-registration. 
The samples were first optically imaged using a DMI 3000 B inverted microscope 
(Leica Microsystems). Bright-field images of the porous membrane and wire co-
registration marker were acquired using a 40x objective. The sample was then transferred 
to a modified PA microscope previously described.30 Briefly, a Polaris II (New Wave 
Research) with 5 ns pulse width and 20 Hz pulse repetition rate was used to mediate the 
PA signal generation. The 532 nm wavelength beam was used. The resulting PA wave 
from the 532 nm pulsed laser light was measured using a 1 mm needle hydrophone 
(Precision Acoustics LTD), amplified using a 5073PR ultrasound receive amplifier 
(Olympus), and digitized using an CompuScope 12400 oscilloscope (Gage Applied 
Technologies). The PA intensity at each point was determined by the time of flight from 
the sample to the hydrophone, ca. 3.5 μs. To speed up the detection, the samples were 
scanned using two different spot sizes. The low resolution scan (100 μm spot size, 
90 mJ/cm2 fluence, 50 μm translation step size) was used to coarsely scan the sample. 
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After regions were identified, a high resolution scan (8 μm spot size, 90 mJ/cm2 fluence, 
and 4 μm translation step size) was used to determine the distribution of the nanoclusters 
with subcellular resolution. 
3.3.2 Results and Discussion 
Photoacoustic imaging of nanocluster-labeled cells in tissue mimicking phantoms  
Since magneto-plasmonic nanoparticles can be advantageous in a number of 
emerging biomedical applications including magnetic capture and simultaneous PA 
detection of CTCs, we evaluated nanocluster performance with PA imaging in the red-
NIR region where blood and biological tissues are more transparent. A series of PA 
images at multiple wavelengths were acquired from A-431 cancer cells labeled with anti-
EGFR nanoclusters and primary 6 nm particles (Figure 3.5). The use of nanoclusters 
increased the strength of PA signal from labeled cells in the NIR region by more than 4 
times as compared with primary particles (Figure 3.5D). This quality makes the 
nanoclusters an attractive agent for in vivo imaging where absorption from endogenous 
chromophores, such as hemoglobin, is significantly reduced in the NIR region.31 
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Figure 3.5 Photoacoustic imaging of labeled A-431 cells in tissue-mimicking cell 
phantoms. The cells were labeled with either EGFR-targeted nanoclusters or 
primary particles using the same mass of Au during labeling. (A) Schematic of 
the experimental setup for combined ultrasound and photoacoustic imaging. 
(B) Combined ultrasound and photoacoustic images of cell phantoms: 
unlabeled cells (top row), nanocluster labeled cells (middle row), and primary 
particles labeled cells (bottom row). (C) A plot of un-normalized PA signal 
intensity integrated over cell inclusions in the phantom as a function of 
wavelength. (D) The ratio of PA signal intensities from nanocluster labeled 
cells to primary particles labeled cells as a function of wavelength.    
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Magnetic capture efficiency 
Previously, we showed that primary 6 nm magneto-plasmonic nanoparticles can 
be used for magnetic capture of cancer cells spiked in whole blood.24 Here, we compared 
the performance of primary particles with magneto-plasmonic nanoclusters. The same 
mass of either anti-EGFR antibody conjugated primary particles or targeted nanoclusters 
were used to label the same amount of A-431 cells. Then, labeled cells were placed in a 1 
cm cuvette with a permanent magnet positioned on one side (similar to the set-up shown 
in Figures 2.7B and 2.7C). The efficiency of cell separation was determined by 
comparing the amount of magnetically-trapped cells and cells in a control cuvette without 
a magnet: 
1−
𝑐𝑒𝑙𝑙  𝑐𝑜𝑢𝑛𝑡  𝑓𝑟𝑜𝑚  𝑚𝑎𝑔𝑛𝑒𝑡  𝑡𝑟𝑒𝑎𝑡𝑒𝑑  𝑠𝑎𝑚𝑝𝑙𝑒
𝑐𝑒𝑙𝑙  𝑐𝑜𝑢𝑛𝑡  𝑓𝑟𝑜𝑚  𝑐𝑜𝑛𝑡𝑟𝑜𝑙  (𝑛𝑜  𝑚𝑎𝑔𝑛𝑒𝑡) ×100% 
The results demonstrate enhanced magnetic cell separation by nanoclusters in shorter 
time periods (Figure 3.6), which is a key improvement because there is a critical need for 
development of faster CTC assays, especially in point-of-care applications. The capture 
yield of nanoclusters achieved ca. 93% after a 10 min magnetic incubation while the 
primary particles showed just ca. 70% capture efficiency at this time point. Hence, 
immunotargeted nanoclusters provide a more efficient agent for molecular specific 
magnetic separation of cells of interests.  
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Figure 3.6 Magnetic capture efficiency as a function of time for A-431 cells labeled with 
either EGFR-targeted primary particles or nanoclusters. The experiment was 
carried out using the same approach as shown in Figures 2.8B and 2.8C. The 
bar graph shows a capture yield that was calculated as following: (1 – 
([number of cells in suspension at a given time]/[number of cells before 
incubation with a magnet])) × 100%.    
Detection of spiked cancer cells in whole blood 
To illustrate the feasibility of CTC enrichment from whole blood using hybrid 
nanoclusters, two samples were prepared, blood only and blood spiked with A-431 cancer 
cells. The high contrast of the low resolution PA images indicated the presence of 
nanocluster-labeled cells (Figure 3.7A). The high resolution PA image provides the 
distribution of nanoclusters with subcellular resolution (Figure 3.7B). The spatial 
distribution of the nanoclusters correlates well with the positions of the cells in the bright-
field image (Figure 3.7C). In contrast, the low resolution PA image of blood only group 
indicated that neither labeled cancer cells nor blood cells were present and 8 µm pores did 
not generate PA signal (Figure 3.7D and 3.7E).  
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Figure 3.7 Photoacoustic and bright-field images of an enriched sample containing spiked 
cancer cells in whole blood (A – C) and an enriched sample containing whole 
blood only (D – E). (A) Low resolution PA images. (B) High resolution PA 
image and (C) bright-field image from the open red box in (A). (D) Low 
resolution PA images. (E) Bright-field image from the open red box in (D). 
Bright-field optical image co-registers with the photoacoustic image using a 
marker at the top right corner. The black dots in the optical image are 
membrane pores. The arrows in (B) and (C) show the labeled cancer cells in 
the photoacoustic and the optical images. 
Although PA imaging alone can easily enumerate CTCs from blood cells, cases of 
high number of cancer cells or circulating tumor microemboli (multicellular aggregates 
or clusters of tumor cells) make accurate quantification difficult. This deficiency can be 
overcome by the combination of the PA imaging with optical imaging, thus the co-
registration of images facilitates characterization and enumeration of CTCs. Furthermore, 
the sensitivity of PA imaging primarily depends on the nanoparticle labeling specificity 
of the targeted moiety. This detection method may compromise its efficiency due to the 
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tumor heterogeneity. Therefore, the introduction of a cocktail of nanoclusters against 
multiple biomarkers may prove to be essential for accurate CTC screening.   
3.4 CONCLUSIONS 
Sensitive and quantitative assessment of changes in circulating tumor cells CTCs 
help in cancer prognosis and in the evaluation of therapeutics efficacy. However, 
extremely low occurrence of CTCs in the peripheral blood (approximately one to few 
CTCs per billion blood cells) and potential changes in molecular biomarkers during the 
process of epithelial to mesenchymal transition create technical hurdles to the enrichment 
and enumeration CTCs. Recently, efforts have been directed toward development of 
antibody-capture assays based on the expression of the common biomarker - the 
epithelial cell adhesion molecule (EpCAM) of epithelium-derived cancer cells. Despite 
some promising results, the assays relying on EpCAM capture have shown inconsistent 
sensitivity in clinical settings and often fail to detect CTCs in patients with metastatic 
cancer. We have addressed this problem by the development of an assay based on hybrid 
magnetic/plasmonic nanocarriers and a microfluidic channel. In this assay cancer cells 
are specifically targeted by antibody-conjugated magnetic nanocarriers and are separated 
from normal blood cells by a magnetic force in a microfluidic chamber. Subsequently, 
immunofluorescence staining is used to differentiate CTCs from normal blood cells. We 
demonstrated in cell models of colon, breast and skin cancers that this platform can be 
easily adapted to a variety of biomarkers, targeting both surface receptor molecules and 
intracellular biomarkers of epithelial-derived cancer cells. Experiments in whole blood 
showed capture efficiency greater than 90% when two cancer biomarkers are used for 
cell capture. Thus, the combination of immunotargeted magnetic nanocarriers with 
microfluidics provides an important platform that can improve the effectiveness of 
 75 
current CTC assays by overcoming the problem of heterogeneity of tumor cells in the 
circulation. In addition, we explored the feasibility of PA imaging to detect CTCs in 
whole blood. We demonstrated excellent detection sensitivity delineating the distribution 
of hybrid nanoclusters targeting the cancer cells on a porous membrane. The work paves 
the way for a novel CTC detection approach which utilizes immunotargeted magneto-
plasmonic nanoclusters for a simultaneous magnetic capture and PA detection of CTCs. 
Thus, the post-processing steps can be minimized to prevent cell loss and a quick CTC 
readout can be established for better determination of the patient prognosis and assess 
tumor sensitivity to anticancer therapy. 
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Chapter 4: Development of Magnetically Guided Cell Delivery Methods 
for Adoptive Cell Therapy of Cancer 
4.1 INTRODUCTION 
Adoptive cell therapy (ACT) has emerged as an effective treatment for cancer 
patients, especially for metastatic melanoma.1 ACT is a form of transfusion therapy 
which contains the infusion of selected T cells, often along with vaccines or growth 
factors to augment the impact in vivo of the transferred cells.2 Anti-tumor lymphocytes 
are selected with appropriate effector functions and subsequently expanded ex vivo before 
reinfusion. Since effective therapeutic effect highly depends on the presence of anti-
tumor lymphocytes at the tumor region, a very large cell number (>1010 cells) per dose is 
usually demanded to seek out and kill cancer cell in vivo.3 However, recent clinical 
studies demonstrate that inefficient homing of T cells becomes a rate-limiting step in 
anti-tumor efficacy, thus causing approximately half of metastatic melanoma patients fail 
to respond to the treatment.4-6 Indeed, analysis of the transferred cells showed a lack of 
persistence in vivo. Less than 0.1% of the cells remained in the circulation in one week 
after infusion.1 In fact, the majority of infused T cells have been found in lung, liver, and 
spleen, whereas less than 1% of the total transferred cells homed to tumor.5, 7  
Different strategies have been employed to improve the homing efficiency of 
ACT. For example, introduction of an immunodepleting preparative regimen given 
before ACT resulted in a better T cell-to-target cell ratio at the tumor site, because the 
lymphodepletion can eliminate T regulatory cells and lymphocytes which usually 
compete with infused cells for homeostatic cytokines.8 In addition, normal T cells can be 
genetically encoded with specific T-cell receptors, such as chimeric antigen receptors 
(CAR), which enhance the avidity of T cells for tumor-specific antigens and thereby 
improve anti-tumor efficacy.9 Furthermore, chemokine signatures within tumor 
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microenvironment can be adjusted by genetically modified tumor-specific T cells.10 Cells 
with corresponding chemokine receptors can migrate along with a chemokine gradient 
and initiate T cell-mediated antitumor immune responses.11 Despite the promising results 
emerging from these improvements, several problems still need to be addressed. Recent 
studies have reported on-target toxicity to normal tissue following ACT of CAR-
modified T cells in patients, thus eliciting the safety concern for this type of therapy.12 
Another major hurdle of ACT is the lengthy isolation and expansion process (4-16 
weeks) to produce a large number of antigen-specific T cells. It may not be feasible for 
patients with progressive disease.13 These problems prompt us to develop a magnetic-
guided cell delivery approach with the expectation to enhance T cell homing efficiency 
(Figure 4.1), thus diminishing the cell dose and shortening laboratory preparation time. 
    
 
 
Figure 4.1 Conceptual cartoon of the magnet-guided delivery of cytotoxic T cells for 
adoptive cell therapy of cancer.    
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Magnetic nanoparticles have been received much attention due to their high 
biocompatibility and versatile applications for human health.14 Cells labeled with 
magnetic nanoparticles are being explored for a range of applications, including magnetic 
resonance imaging 15, magnetic drug delivery16, 17, and stem cell-based therapeutics.18 In 
particular, magnetic particle-assisted positioning of human cells has been demonstrated to 
repair injured blood vessels,19 heart,20 and articular cartilage.21 This strategy appears to be 
highly interesting for ACT because magnet-oriented positioning enables systemic 
delivery of the T cells aiming at tumor tissues. Further release of transferred cells from 
the tumor site is feasible by removing external magnetic stimuli. In addition, iron oxide-
based magnetic nanoparticles offer unique properties for cell tracking and monitoring by 
MRI, thereby allowing us to delineate infused T cell survival, response and migration in 
vivo which has been a lack of deep understanding.22 
Here, we tested the concept of nanoparticle-mediated cell labeling for controllable 
immune cell positioning. We engineered immune cells with magnetic properties by using 
nanoparticle platform derived from Chapter 2. Two cell labeling strategies were 
implemented: (1) cellular internalization of magnetic nanoclusters (described in Chapter 
4.2) and (2) selective cell surface labeling by immunotargeted magneto-plasmonic 
nanoclusters (described in Chapter 4.3). The first strategy involved synthesis of iron 
oxide nanoclusters with particle surface modification to facilitate the cellular uptake and 
increase the biocompatibility. A macrophage cell line was loaded with biocompatible iron 
oxide nanoclusters and the response of engineered macrophages to magnetic stimuli was 
investigated. A series of feasibility studies for the magnet-assisted cell positioning was 
explored under simulated physiological conditions in vitro. The second strategy utilized 
immunotargeted magneto-plasmonic nanoclusters to label and enrich a subset of immune 
cells, cytotoxic T lymphocytes (CTL), which can kill cancer cells directly.23 The viability 
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and in vitro magnetic response of CTL labeled with hybrid nanoclusters were evaluated. 
These results pave the way for an in vivo pilot study to investigate whether the magnet-
guided cell delivery method can enhance T cell recruitment in tumor. 
4.2 THE METHOD BASED ON CELLULAR INTERNALIZATION OF MAGNETIC 
NANOCLUSTERS 
4.2.1 Materials and Methods 
Synthesis and characterization of iron oxide nanoclusters 
The 5 nm iron oxide nanoparticles were prepared according to a previously 
published protocol.24 Briefly, 1 mM iron(III) acetylacetonate was mixed in 10 mL phenyl 
ether, followed by addition of 3 mM oleic acid, 2 mM oleylamine, and 3 mM 1,2-
hexadecanediol (Fisher Scientific). The mixture was stirred vigorously, heated to 260 °C, 
and refluxed for 1 h yielding a suspension of highly uniform 5 nm Fe3O4 nanoparticles.  
To synthesize nanoclusters, one volume of a suspension of the 5 nm Fe3O4 
particles (5 mg/mL by total weight) in hexane was mixed with ten volumes of deionized 
water containing an anionic surfactant − sodium dodecyl sulfate (SDS, Sigma Aldrich) at 
2.8 mg/mL.25 The mixture was placed in a sonicator bath (Model 1510, Branson) for 2 h. 
After starting the sonication, the solution was shaken by hand gently to facilitate mixing 
between the phase containing primary hybrid nanoparticles and the bottom aqueous 
phase. The solution was heated in a water bath at 80 °C for 10 min to remove hexane. 
Nanoclusters with 130 nm in diameter were separated using the following sequence of 
centrifugation steps: (1) large nanoclusters, i.e. > 180 nm, were removed by 
centrifugation at 100 ×g for 30 min and the sediment was discarded; (2) the supernatant 
from step 1 was centrifuged at 400 ×g for 30 min and the sediment was collected and 
resuspended in 0.2 mM Na Citrate (Fisher Scientific) with 10 min sonication. 
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To coat magnetic nanoclusters with poly-l-lysine (PLL), the 130 nm magnetic 
nanocluster (1 mL at 0.15 mg Fe/mL) was spun down (830 ×g for 10 min), removed 
supernatant, and resuspended in 1 mg/mL PLL-FITC labeled (Sigma Aldrich). After 1 h 
sonication, the nanoclusters were incubated in oven at 70°C for 1 h. The solution was 
cooled down to room temperature, spun down again to remove excess PLL, and finally 
resuspended in PBS. The magnetic nanoclusters were characterized for morphology, size 
distribution, and charge using transmission electron microscopy (FEI TECNAI G2 F20 
X-TWIN TEM at 80 keV.), dynamic light scattering (DLS, Beckman Coulter), and zeta 
potential measurements (Beckman Coulter), respectively. 
Cellular uptake of magnetic nanoclusters  
Murine macrophage cell line (J744.A1) were purchased from ATCC and grown in 
Dulbecco's Modified Eagle Medium (Life Technologies) supplemented with 5 % fetal 
bovine serum (FBS, Hyclone). When confluent, the sterile PLL-coated nanoclusters (100 
μL at 10 μg/mL) were added to the cell culture medium. After incubation overnight, the 
cells were washed three times with PBS to remove excess magnetic nanoclusters. The 
dark-field and fluorescence images were taken using 20×, 0.5-NA, Leica DM6000 
upright microscope. 
Cell viability assay 
J744.A1 cells (5×103 cells) were grown in 96-well and incubated with sterile 
PLL-coated magnet nanoclusters at two different concentration, 8.4 and 34.4 μg/mL for 
24 h at 37°C. Afterwards, the cells incubated with magnetic nanoclusters and the 
untreated cell control were then washed twice with PBS and mixed with 100 μL MTS 
reagent, a mixture of MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-
(4-sulfophenyl)-2H-tetrazolium) (0.32 mg/mL, Promega) and PMS (phenazine 
methosulfate) (7.3 μg/mL, Sigma Aldrich) in cell culture media. Absorbance at 490 nm 
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was taken 3 h after the addition of the MTS reagent using a BioTek Synergy HT micro-
titer plate spectrophotometer; the absorbance is proportional to the number of 
metabolically active live cells in a sample. 
In vitro magnetic attraction assay  
First, we investigated whether internalized magnetic nanoclusters can respond to 
an external magnetic field. J744.A1 cells (5×105 cells) were grown on a coverslip and 
labeled with PLL-coated magnetic nanoclusters. After 24 h incubation at 37°C, the 
excess nanoclusters were washed out. A magnet (1 × 1 × 1 cm, NdFeB, K&J Magnetics) 
was positioned at one corner of the coverslip for 1 min, followed by imaging using 20×, 
0.5-NA dark-field and bright-field objective under Leica DM6000 upright microscope.   
Furthermore, we seeded magnetic nanocluster-loaded J744.A1 into a collagen I 
phantom as previously described.26 The phantom was placed in a 6-well culture dish and 
undisturbed for 1 h for cell adhesion. A magnet (1 × 1 × 1 cm, NdFeB, K&J Magnetics) 
was then introduced and located next to the phantom. A series of bright-field pictures 
from the region of interest (ca. 5 mm from the magnet) was recorded as a function of 
time using an inverted bright-field microscopy (Olympus DP71).  
To test the magnetic trapping in a flow condition, the magnetic nanocluster-
loaded J744.A1 cell suspension was loaded into a reservoir that was connected to a tube 
(1/32” inner diameter). The other side of the tube was connected to a syringe pump to 
control flow rate at 10 mL/min. A magnet (1 × 1 × 1 cm, NdFeB, K&J Magnetics) was 
then placed underneath the tube, followed by recording a video with the presence of the 
magnet using an inverted bright-field microscopy (Olympus DP71). 
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4.2.2 Results and Discussion 
Iron oxide nanoclusters  
The synthetic scheme of PLL coated-Fe3O4 nanoclusters was shown in Figure 
4.2A.  A microemulsion approach was used to self-assemble 5 nm iron oxide seeds 
(Figure 4.2B) into nanoclusters (Figure 4.2C). The nanocluster formation utilizes a 
negatively charged amphiphilic surfactants SDS with a hydrophobic moiety to hold 
together the primary particles inside the cluster, through hydrophobic van der Waals 
interactions, and a polar group to provide aqueous solubility. The deposition of positively 
charged PLL layer onto the nanoclusters was then carried out by electrostatic 
interaction.27 PLL is   a polycationic polymer with great biocompatibility and solubility in 
water that has  been used as carriers for gene delivery and coating materials for various 
purposes.28 It contains plentiful active amino groups and a flexible molecular backbone 
which makes chemical modification easily.29 Furthermore, the PLL coating has been 
shown to enhance cellular uptake of particles.30 Thus, we coated our nanoclusters with 
PLL to facilitate cellular internalization of magnetic nanoclusters. The zeta potential of 
as-synthesized nanoclusters capped by SDS is −14.93 ± 0.63 mV. After coating 
nanoclusters with PLL, the zeta potential shifts to positive charge, +17.69 ± 0.44 mV. 
The hydrodynamic diameter of nanoclusters measured by dynamic light scattering 
indicates an increase of 33 nm (137.5 nm to 170.5 nm) after coating with PLL. Therefore, 
the change of surface charge and the increase of hydrodynamic diameter of the 
nanoclusters suggest the successful surface modification. 
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Figure 4.2 Iron oxide nanoclusters synthesis and characterization. (A) Synthetic scheme 
of poly-l-lysine coated magnetic nanoclusters. The charge indicates the zeta 
potential changes before and after coating with poly-l-lysine. TEM images of 
5 nm iron oxide seeds (B) and nanoclusters with a diameter ca. 130 nm (C). 
Cellular internalization of magnetic nanoclusters  
To evaluate the cellular internalization of magnetic nanoclusters, we co-cultured 
PLL-FITC-modified iron oxide nanoclusters with a macrophage cell line, J744.A1. The 
nanoclusters were found to be internalized after 4 h incubation as determined by bright-
field, dark-field, and fluorescence imaging (Figure 4.3). The brown color in the bright-
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field image indicates the presence of nanoparticles, whereas untreated cell presents nearly 
transparent color (Figure 4.3). In dark-field images, a bright yellow color shows the 
uptake of the nanoclusters by macrophages, whereas a gray-bluish color corresponds to 
the endogenous scattering of the untreated cells. The effective cellular uptake can be 
further evidenced by the co-registration with the fluorescent images and the bright-field 
and dark-field optical images (Figure 4.3). Indeed, macrophages are capable of ingesting 
particular substances by phagocytosis, such as bacteria, damaged and dead cells, and 
foreign particles.31 In our case, positive surface charge from the PLL modification further 
facilitated cellular uptake.  
 
Figure 4.3 Images of macrophages labeled with poly-l-lysine-FITC coated iron oxide 
nanoclusters. Columns correspond to macrophages without and with particle 
loading. Rows show results obtained with (from top to bottom): bright-field, 
dark-field, and fluorescence microscope. 
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Biocompatibility of magnetic nanoclusters  
Next, we investigated whether intracellular localization of the magnetic 
nanoclusters induced cytotoxicity. The viability assay was carried out by exposing 
macrophage cells with the nanoclusters for 24 h. At the concentration of 8.6 μg/mL, cell 
viability was similar to the untreated macrophages, suggesting high biocompatibility of 
the nanoclusters at this level (Figure 4.4). In the case loading with high concentration, 
34.4 μg/mL, cell viability kept over 70%. Indeed, several studies have also shown that 
labeling cells with Fe3O4 nanoparticles did not affect the viability, proliferation, and 
differentiation capacity of cells.15, 18, 32 Thus, we used the magnetic nanoclusters at a 
concentration of 10 μg/mL which is not cytotoxic and shows high cellular internalization 
efficiency (Figure 4.3). 
 
Figure 4.4 Viability assay of poly-l-lysine-coated iron oxide nanoclusters with 
macrophages. Cells were incubated with two different concentrations of the 
nanoclusters for 24 h followed by performing MTT cell viability assay. 
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Magnetic attraction of nanocluster-labeled macrophages under static conditions 
Trafficking cells to a desirable region can be achieved in many ways, such as 
introducing a chemoattractants gradient or manipulating magnetic cells with a magnetic 
field.16, 33 To elicit a significant therapeutic effect, functional cells should be trafficked to 
a region of interest in sufficient numbers. By yielding the cells with magnetic properties, 
cells can be presumably induced with preferential movement by applying and adjusting 
an external magnetic field. Thus, we conducted a series of experiments in vitro to 
evaluate the magnetic response of magnetic nanocluster-labeled cells. First, the 
macrophages were grown on a glass coverslip and labeled by the magnetic nanoclusters. 
A magnetic gradient field generated by a permanent magnet was then introduced 
underneath the coverslip (Figure 4.5A and 4.5B). The nanoclusters inside the cells close 
to the magnet (ca. 1.4 mm with 0.4 T) experienced the strong magnetic field and 
realigned its distribution accordingly (Figure 4.5C and 4.5D). In contrast, the 
nanoclusters away from the magnet (ca. 14 mm with 0.03 T) showed no response to the 
magnet (Figure 4.5E and 4.5F).  
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Figure 4.5 Magnet attract assay of magnet particle-loaded macrophages. (A) 
Experimental procedure. (B) Magnetic field distribution under the sample 
area. (C and E) Dark-field images were taken from the red circle (1.4 mm 
away from the magnet) and blue (14 mm away from the magnet), respectively. 
(D and F) Bright-field images were taken from the open yellow square from C 
and E, respectively. 
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We speculate that the realignment of magnetic nanoclusters can provide a source 
of force for attracting cells under a magnetic field. Therefore, we further embedded the 
magnetic nanocluster-labeled macrophages into a tissue-mimicking phantom. A magnet 
was applied externally next to the phantom (Figure 4.6A). A series of bright-field 
pictures from the region of interest (ca. 5 mm from the magnet) shows that the cells 
moved toward the magnet as time evolved (Figure 4.6B). The average speed is 0.46 ± 
0.42 μm/min. A quicker movement can be expected when the cells are closer to the 
magnet. These findings demonstrate the potential to remotely control the engineered cells 
to specific sites. Even for the targeting site located in deep tissue, cells can possibly 







Figure 4.6 Motility assay of magnet particle-loaded macrophages as a function of time. 
(A) The macrophages were embedded in 3D tissue-mimicking phantom and 
an external magnet was placed at right-hand side. (B) The images were taken 
with ten min interval illustrated by the color locus. The average speed of the 
cell movement is 0.46 ± 0.42 μm/min. 
Magnetic attraction of nanocluster-labeled macrophages under flow conditions 
In addition to controllable  migration, the adhesion of immune cells under flow 
condition and subsequent extravasation into surrounding tissues play the important step 
for site-specific targeting. In this assay, the magnetic nanocluster-labeled macrophages 
were loaded into a tube flowing at 10 mL/min which mimicked their passage through 
flowing blood vessels (Figure 4.7A).34 The attraction of the cells was visualized under 
bright-field microscopy in the presence or absence of a magnetic field. In Figure 4.7B, 
introduction of the magnet resulted in a significant accumulation of labeled macrophages. 
In contrast, the labeled macrophages flowed by in the absence of the magnet. The 
nanocluster-loaded macrophages demonstrated high magnetic force so that they can be 
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magnetically trapped even at the fast flow condition. Overall, the internalization of 
magnetic nanoclusters creates efficient  positioning of cells and enables their 
stable  engraftment at specific  sites. The engineered cells  could potentially migrate to 





Figure 4.7 Magnetic attraction of nanocluster-labeled macrophages under flow 
conditions. (A) Schematic cartoon of the experimental setup. (B) Magnetic 
trapping study with and without the presence of a magnetic field under 10 
mL/h flow rate. The yellow arrows indicate the accumulation of cells. 
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4.3 THE METHOD BASED ON SELECTIVE CELL SURFACE LABELING BY 
IMMUNOTARGETED HYBRID NANOCLUSTERS 
4.3.1 Materials and Methods 
Synthesis of magneto-plasmonic nanoclusters and antibody conjugation 
Hybrid magneto-plasmonic nanoparticles were synthesized in three steps as 
previously described (Chapter 2). First, 5 nm magnetic core nanoparticles were 
synthesized using thermal decomposition of Fe(acac)3 (1 mmol, Sigma Aldrich) in the 
presence of oleic acid (2 mmol, Fisher), oleylamine (2 mmol, Fisher), 1,2-hexadecanediol 
(5 mmol, Sigma Aldrich), and phenyl ether (10 mL, Sigma Aldrich) at 250 to 260 °C 
with 1 h reflux. Second, a thin gold shell was then deposited onto the magnetic core 
nanoparticles. Five mL of as-synthesized magnetic nanoparticle suspension was mixed 
with gold acetate (1.1 mmol), oleic acid (0.75 mmol), oleylamine (3.0 mmol), 1,2-
hexadecanediol (3 mmol), and 15 mL phenyl ether. The reaction was heated up to 180 °C 
and kept under reflux for 1 h. The resultant 6 nm seed particles were readily dispersed in 
hexane. Finally, the hybrid magneto-plasmonic nanoparticles were synthesized via oil-in-
water microemulsion method. One volume of a suspension of the seed particles (5 
mg/mL by total weight) in hexane was mixed with ten volumes of deionized water 
containing sodium dodecyl sulfate (2.8 mg/mL, Sigma Aldrich). After sonication (Model 
1510, Branson) for 2 h, the solution was heated in a water bath at 80 °C for 10 min to 
remove residual hexane. The hybrid magneto-plasmonic nanoparticles with ca. 130 nm in 
diameter was collected by centrifugation at 400 ×g for 30 min and resuspended in 0.2 
mM sodium citrate (Sigma Aldrich). 
Antibody conjugation to magneto-plasmonic nanoclusters 
Alexa Fluor 647 anti-mouse CD8 antibody (Biolegend) was thiolated at the 
carbohydrate moiety on Fc portion.35 Briefly, 100 μL of antibody solution (1 mg/mL in 
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HEPES, pH 7.2) was incubated with 10 μL of 100 mM NaIO4 (Sigma Aldrich) in dark 
for 30 min at room temperature. The reaction was quenched by 500 μL 1x PBS, followed 
by mixing with 2 μL of 46.5 mM linker solution (dithiolaromatic PEG6-CONHNH2, 
SensoPath) for 60 min at room temperature. Afterwards, the purified thiolated antibody 
solution was recovered by a 10k MWCO centrifuge filter (3,250 ×g for 20 min at 8 °C) 
and resuspended in 1x PBS. To conjugate antibodies to NP, 1 μL of thiolated antibodies 
(1 mg/mL) was mixed with 100 μL NP at O.D ca. 1.0 for 2 h at room temperature with 
mild shaking. To passivate the remaining NP surfaces, 10 μL of 10−3 M methoxyl 
polyethylene glycol thiol (5 kDa, SensoPath) was added to the solution with 20 min 
incubation at room temperature. Finally, the antibody-conjugated NPs were collected by 
centrifugation at 830 ×g for 3 min and resuspended in 100 μL 1x PBS. 
Labeling and magnetic enrichment of CD8+ T cells 
A single cell suspension from lymph nodes or spleens was derived from sacrificed 
mice. First, mouse lymph nodes or spleens were dissected out and washed in chilled PBS. 
Lymph node or spleen tissue was mechanically teased by clean forceps. A single cell 
suspension was prepared by passing through a 70 μm sterile filter and washed by 1x PBS 
through the mesh. The cells were then cultured in RPMI-1640 supplemented with 5% 
fetal bovine serum, 2 mM L-glutamine and 25 μg/mL Gentamicin (Life Technologies). 
Before NP labeling, 1 μg of Fc block antibody, CD16/CD32 (Biolegend), was added to 
100 μL of suspended cells (ca. 1-3×106 cells) for 20 min at room temperature. Then, 100 
μL of Alexa Fluor 647 anti-CD8 antibody conjugated NPs (0.05 nM) was mixed with 
cells for 1 h at room temperature. Cells were washed from any unbound NP by adding 5 
mL PBS and centrifuging at 182 ×g for 3 minutes. The supernatant was discarded and the 
cells were resuspended in 1 mL PBS. Dark-field and fluorescence images of the cells 
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were performed using a Leica DM6000 upright microscope configured with 20×, 0.5-NA 
dark field objective, fluorescence filter cube (Chroma), and a Xe-lamp illumination. 
For magnetic enrichment, labeled cells were first passed through a 30 μm filter 
(Miltenyi Biotec) to remove potential cell aggregates. The cell suspension was loaded 
into a PBS-rinsed MS column (Miltenyi Biotec) in presence of the MACS magnet. The 
column was then washed with 1 mL PBS for three times. The nanocluster-labeled CD8+ 
T cells retained in the MS column, whereas the non-labeled cells flowed through the MS 
column. Afterwards, the MS column was removed from the MACS magnet and washed 
out through with 1 mL PBS, resulting in release of NP-labeled CD8+ T cells from the MS 
column. The proportion of CD8+ T cells present in the total cell population was accessed 
by flow cytometry (BD LSRFortessa). 
Measurement of cell viability after labeling with hybrid nanoclusters 
A single cell suspension from spleens (1-5×106 cells in 100 μL) was labeled by 
Alexa Fluor 647 anti-CD8 antibody conjugated NPs (100 μL at 0.05 nM) for 1 h at room 
temperature. The cells were then washed with 5 mL PBS and resuspended in 3 mL cell 
culture medium. After 24 h incubation in CO2 incubator at 37 °C, the cells were washed 
with 2 mL PBS and stained with 100 μL PBS containing 0.5 μg Zombie Violet dye 
(Biolegend) in dark for 20 min at room temperature. Afterwards, the cells were washed 
with 2 mL buffer (PBS containing 2% BSA) and resuspended in 100 μL PBS, followed 
by flow cytometry analysis (BD LSRFortessa). 
In vitro Magnetic Trapping Test 
The cells were derived from sacrificed transgenic mice expressing red fluorescent 
protein on CD2. The nanocluster labeling process was described above. Nanocluster-
labeled cells or unlabeled cells (1.1×105 cells in 20 μL PBS) were distributed to a single 
well from inner side of a 96-well lid. A disc magnet (1 mm diameter × 0.5 mm thick, 
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NdFeB, N50, SuperMagnetMan) was placed toward the center of the well and a round 
glass coverslip was applied onto the top of the well. After incubation with the magnet for 
1 min, the images were captured by TCS SP5 RS laser resonant scanning microscope 
using 4X objective (Leica Microsystems). 
To investigate whether the nanocluster-labeled cells can be magnetically 
positioned, labeled cells (1.1×105) were distributed to a single well from inner side of a 
96-well lid, followed by capping with a round glass coverslip. A disc magnet (1 mm 
diameter × 0.5 mm thick, NdFeB, SuperMagnetMan) was placed onto the glass coverslip 
with random movement. The images were captured as previously described. 
4.3.2 Results and Discussion 
Cell-based therapies based on anti-tumor lymphocytes are promising approaches 
for cancer immunotherapy.9 The infusion of ex vivo cultured lymphocytes, called 
adoptive cell therapy, has demonstrated its effectiveness in tumor rejection in a few of 
early phase clinical trials.36 The ability to genetically engineer lymphocytes in vitro yields 
further opportunity to increase the avidity of T cells for tumor antigens, thus improving 
the efficacy of ACT.9, 10 In general, an effective cancer immunotherapy to seek out and 
reject cancer cells in vivo highly depends on the presence of large numbers of anti-tumor 
lymphocytes with appropriate homing and effector functions.37 Although ACT involves 
the administration of lymphocytes that can be augmented ex vivo in very large numbers, 
inefficient migration of T cells to tumor tissue is still one major limited factor for ACT.38, 
39 Several lines of evidence have demonstrated that impaired tumor homing of T cells 
causes the disappointing clinical response rates.40 Therefore, strategies to improve the 
migration of T cells to tumor microenvironment can possibly to enhance the efficacy of 
ACT.  
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 Currently, most of the efforts have been focused on the improvement of T cell 
functions, including selection of antigen, antigen presentation systems, or expansion 
methods. For example, T cells from patients have been genetically engineered to express 
a T cell receptor or chimeric antigen receptor to specifically target a tumor-associate 
antigen.41, 42 Several early clinical trials using CAR-modified T cells have shown some 
promising results.43, 44 In addition, researchers have demonstrated a simplified and rapid 
method to expand tumor reactive lymphocytes for ACT, since the existed protocol has 
been criticized for its time-consuming and labor-intensive process.45 However, to date, 
there have been very limited studies to improve ACT from the cell delivery perspective. 
Effective tumor rejection requires not only a sufficient number of activated T cells with 
high avidity that can recognize tumor antigens, but also the ability of these cells to 
migrate to the malignancy sites.37 Thus, we proposed a magnet-guided approach which 
involves manipulating cells ex vivo with magnetic properties followed by precise 
positioning of lymphocytes using an external magnetic field. This novel approach could 
potentially lead to accumulate significant numbers of lymphocytes in tumor lesion and 
thereby achieve its desired therapeutic effect. 
In the past two decades, the control of the interaction between live cells and 
magnetic nanomaterials has been intensively investigated. Magnetic nanomaterials, 
mainly iron oxide nanoparticles, with unique superparamagnetic properties and favorable 
biocompatibility are useful for biomedical applications.46 For example, magnetic labeling 
of living cells has been successfully applied to diagnostic imaging and regenerative 
medicine for a variety of diseases, including neurological disease, myocardial infarction, 
and arthritis.47-49 The use of “magnetic cells” provides not only the use in MR imaging for 
tracking and monitoring of transferred cells but also the remote manipulation of cells 
under a magnetic stimulus.19, 50 However, we found that there are very few studies 
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utilizing the magnetic cell concept to combat one of the most prevalent diseases, cancer. 
Muthana et al. showed that administered magnetic NP-loaded monocytes can be pulled 
out from the circulation and pass across an endothelial cell barrier into the tumor mass.51 
However, their focus tends to utilize cells as cellular delivery vehicles for anti-cancer 
gene therapy. This is less straightforward than delivering either cytotoxic T lymphocytes 
or tumor-infiltrating lymphocytes to kill cancer cells directly. Thus, we present a novel 
approach to magnetically label and enrich cytotoxic T lymphocytes for in vivo reinfusion 
and subsequently positioning under an external magnetic field. 
Magneto-plasmonic nanoclusters 
We use our proprietary magneto-plasmonic nanoclusters to render cytotoxic T 
cells magnetic properties. The whole construct of the immunotargeted hybrid 
nanoclusters can be seen at Figure 4.8A. The hybrid nanoclusters were synthesized via 
self-assembly of the constituent Fe3O4 core−Au shell nanoparticles. The TEM image of 
nanoparticles (Figure 4.8B) shows a spherical shape with a size distribution of 130 ± 26 
nm (Figure 4.9C). A distinctive plasmonic resonance peak was located ca. 556 nm 
(Figure 4.9D). The use of hybrid nanoclusters has been demonstrated enhancing magnetic 
force while preserving the superparamagnetic properties of the nanoparticles. Indeed, the 
hybrid nanoclusters can be quickly isolated from a colloidal suspension using a 
permanent magnet (inset in Figure 4.9D). Monoclonal targeted antibodies were attached 
to the nanoclusters using our proprietary directional conjugation through the Fc portion 
that leaves the antigen binding sites on the Fab moiety available for targeting.35 This 
directional conjugation chemistry has been shown to diminish potential non-specific 
interactions through Fc receptors.52-55 Subsequently, methyl-PEG-thiol is added to 




Figure 4.8 Characterization of magneto-plasmonic nanoparticles. (A) Schematic 
constituents of an immunotargeted magneto-plasmonic nanoparticles. (B) 
TEM image, (C) size distribution, and (D) UV-Vis spectrum of magneto-
plasmonic nanoparticles. The insertion in (D) shows the separation of 




Labeling CD8+ T cells 
In this study, we chose anti-CD8 antibodies as our targeting biomarker which 
allows us to target cytotoxic T cells. The labeling specificity was first determined by 
comparing the cell binding using dark-field and fluorescence imaging. In Figure 4.9A, 
the cells from nanocluster-treated group show that bright orange color around their 
surface which is associated with strong light scattering from nanoclusters. The orange 
color matches well with the fluorescent signal from Alexa Fluor 647 anti-CD8 antibodies, 
therefore supporting the effective nanoparticle-antibody conjugation. In addition, we 
characterized the labeled cells using flow cytometry. Figure 4.9B shows similar 
expression of CD8 between nanoparticle- and antibody-treated samples, indicating the 
specific nanocluster labeling to CD8+ T cells. It is also noted that the CD8+ sub-
population was slight lower for nanoparticle-labeled group (25.0%) in comparison with 
antibody alone group (31.5%). This phenomenon has been reported elsewhere that the 
particles affects binding kinetics between antibody and antigen, thus binding of antibody-
conjugated beads to the cells is slower than that of the antibodies themselves56 
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Figure 4.9 Characterization of T cells labeled by Alexa Flour 647-anti-CD8-conjugated 
nanoparticles using (A) imaging analysis and (B) flow cytometry. The yellow-
orange color in the dark-field images is associated with binding of the 
nanoparticles to the cells; unlabeled cells show greyish color that represents 
the intrinsic scattering properties of cells. CD2 is a marker for T cells whose 
fluorescent signal was from red fluorescent protein on CD2. Flow cytometry 
analysis shows that CD8+ subset was 25% for nanoparticle-labeled group (red 
solid) in comparison with 31.5% for antibody-alone group (blue solid). An 




Magnetic enrichment of CD8+ T cells 
We investigated whether the labeled CD8+ T cells can be isolated magnetically. 
We used the commercially available magnetic cell sorting apparatus, MACSTM column 
which is widely utilized in biological field.57 In brief, nanoparticle-labeled cells were 
loaded into magnetic cell separation columns filled with ferromagnetic beads, followed 
by introduction of a magnetic field generated by a strong external magnet (Figure 4.10A). 
The cells labeled with hybrid nanoclusters were efficiently retarded in the column and 
unlabeled cells were eluted. The labeled cells were then recovered when the column was 
de-magnetized by removal from the magnetic field. Before separation, 3.9% of the cells 
expressed CD8+ (Figure 4.10B). After magnetic enrichment, the CD8+ T cell population 
increased to 80.5% (Figure 4.10C). In contrast, the un-retained fraction, eluted from the 
column during the washing step, contained only 0.5% of CD8+ T cell population (Figure 
4.10D). The more than 20-fold enrichment rates explained that the hybrid nanocluster-
labeled cells generated enough magnetic strength, thus contributing the high efficiency of 
magnetic enrichment of CD8+ T cells. To the best of our knowledge, it is the first hybrid 




Figure 4.10 Magnetic enrichment of CD8+ T cells from mouse splenocytes. (A) 
Experimental produce for magnetic enrichment. The cells were labeled by 
Alexa Flour 647-anti-CD8-conjugated nanoparticles followed by running 
MACSTM column: before (B), after (C), and eluent of isolation (D) where the 
CD8+ cell subsets are 5.9%, 85%, and 2.2%, respectively. 
Biocompatibility of hybrid nanoclusters 
The utility of nanoparticle-labeled cells for ACT highly depends on the extent of 
cytotoxicity induced by nanoparticles. The cells should be kept viable during nanoparticle 
labeling process and subsequent reinfusion in vivo. Thus, we assessed whether the 
nanocluster labeling would interfere the viability of cells. Several reports have been 
shown the coating on nanoparticles highly determines their biocompatibility.58, 59 Among 
the choice of surfactants, nanoparticles modified with polyethylene glycol achieved 
enhanced biocompatibility.60-62 In our nanoparticle platform, co-attachment of PEG 
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molecules to the nanocluster surface is feasible. The process involves only mixing the 
nanoparticles with methyl-PEG-thiol so that the original surfactants can be exchanged 
with PEG. In the viability assay, a single cell suspension from mouse spleen was labeled 
by anti-CD8-conjugated nanoclusters or antibody alone for 1 h. After washing step, the 
cells were then incubated for 24 h in the CO2 incubator at 37°C. The cells were then 
stained with amine-reactive viability dye. The positive control prepared by heat-killed 
approach showed more than 95% cell death which indicates the effectiveness of this 
viability dye (Figure 4.11B). In contrast, nanoparticle-labeled cells showed the similar 
viability as compared with untreated or antibody-treated cells after 24 h incubation 
(Figure 4.11). Therefore, the great biocompatibility suggests high utility of the hybrid 




Figure 4.11 Flow cytometry evaluation of cell viability on splenocytes treated with 
nanoparticles and incubated for 24 h thereafter. Live and dead cells were 
distinguished by using Zombie Aqua™ Fixable Viability Kit. (A) unstained; 
(B) heat-killed (positive control); (C) untreated (negative control); (D) Alexa 
Flour 647 anti-CD8 Ab; (E) Alexa Flour 647 IgG2a isotype ctrl; (F) Alexa 
Flour 647-anti-CD8-conjugated nanoparticles. Upper quadrants represent the 
live cell population which is distinguished from the killed population at 
lower quadrants. The right quadrants contain events that are positive for the 







In vitro magnetic trapping test 
Cell-based cancer therapies typically rely on intravenous delivery of cells which 
are expected to home to sites of diseases. However, homing efficiency is typically 
inefficient.11, 22, 63 We propose that delivery and retention of cells could be enhanced by 
magnetic labeling of cells and subsequent introduction of an external magnetic gradient at 
the site of interest. To investigate the feasibility of this approach, we first evaluated the 
magnetic attraction of labeled cells under in vitro static conditions. We dropped a tiny 
disc magnet (1 mm diameter × 0.5 mm thick) into a well loaded with nanocluster-labeled 
T cells (Figure 4.12A). The nanoparticle-labeled cells demonstrated strong response to 
the magnetic field gradients and retained at the sites with highest magnetic field gradient 
(Figure 4.12B). In contrast, the unlabeled cells remained in a cell suspension and 
distributed uniformly in the well without disturbance by the magnet. (Figure 4.12B).  
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Figure 4.12 Magnetic attraction assay of nanoparticle-labeled CD8+ T cells under static 
conditions. (A) Experimental procedure. (B) Magnetic attraction of enriched 
CD8+ T cells or unlabeled T cells after incubation of a disc magnet for 1 
min. Green dot line represents the magnet and the red cells are T cells 
from transgenic mice expressing red fluorescent protein on CD2.  
 
 110 
We further investigated whether nanocluster-labeled T cells can be positioned 
under magnetic guidance. The nanocluster-labeled cells were loaded into a small chamber 
created by a well from the inner side of a 96-well lid and a glass coverslip. A disc magnet 
was placed on top of the coverslip. Then, the disc magnet was repositioned at later time 
points (Figure 4.13A). The nanocluster-labeled cells moved toward the magnet when the 
magnet was static at one position. After moving the disc magnet to another region, 
nanocluster-labeled cells shifted to the magnet accordingly (Figure 4.13B). As can be 
seen from the last timeframe in Figure 4.13B, T cells formed a high-density cell cluster 
after removing the magnet. This enhancement of T cell recruitment suggests a high 
potential for therapeutic use. Overall, these in vitro findings clearly indicate that 




Figure 4.13 Magnetic motility assay of nanoparticle-labeled CD8+ T cells. (A) 
Experimatal procedure. (B) Magnetic manipulation of labeled T cells by an 
external magnet. White dot line indicates the location of the magnet (solid 
blue) from the previous time point. Red cells are T cells 






Here, we introduced a concept to mediate immune cells with magnetic properties 
and a magnetic field to improve cellular delivery of ACT. We showed that the immune 
cells were well labeled by the nanoparticles based either cellular internalization or 
selective surface labeling. It is also found that none of the nanoparticle labeling induced 
noticeable cytotoxic to immune cells. Importantly,  the retention of the magnetically 
engineered cells   can be elevated under physiological conditions   by applying a magnetic 
field. These engineered cells can be potentially manipulated to inaccessible areas 
of  tumors with an aid of a magnetic force. Thus, infiltration of immune cells into tumor 
tissues could be expected to reject tumor cells in a more efficient manner. 
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Chapter 5: Conclusions and Future Work 
5.1 CONCLUSIONS 
In Chapter 2, an immunotargeted magneto-plasmonic nanoparticle platform was 
created. The unique feature of the platform is the synthesis of magneto-plasmonic 
nanoparticles of various sizes from primary blocks which also have magneto-plasmonic 
characteristics. This platform yields nanoparticles with a high density of magnetic and 
plasmonic functionalities which are uniformly distributed throughout the nanoparticle 
volume. The dense packing of primary particles does not change their superparamagnetic 
behavior; however, the close proximity of the constituent particles in the nanoclusters 
leads to a greatly improved response to an external magnetic field and strong near-
infrared plasmon resonances. Thus, our approach provides the combination of the 
tunability of magnetic moment without sacrificing superparamagnetic properties and 
strong visible-NIR absorbance, thus addressing many of the major limitations of previous 
synthetic methods. Furthermore, the hybrid nanoparticles can be easily functionalized by 
attaching antibodies through the Fc moiety leaving the Fab portion that is responsible for 
antigen binding available for targeting. We also demonstrated that the choice of the 
suitable surfactant in synthesis of the magneto-plasmonic nanoparticles and subsequent 
surface modification with PEG molecules are both important steps in producing 
biocompatible nanoconstructs. 
In Chapter 3, we utilized the immunotargeted magneto-plasmonic nanoparticle 
platform for labeling of rare cancer cells in the whole blood. The combination of 
nanocarriers and a magnetic microfluidic chip allows highly efficient capture, 
enumeration and molecular characterization of CTCs. Our platform provides flexibility in 
capturing phenotypically different CTCs by using nanocarriers that are targeted to 
different molecular tumor biomarkers; this can significantly improve the effectiveness of 
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CTC assays. Furthermore, the use of targeted nanoparticles allows a straightforward 
extension to multiplexed approaches where capture of cancer cells is carried out by a 
mixture of nanoparticles with different target specificities. Experiments in whole blood 
showed capture efficiency greater than 90% when two cancer biomarkers are used for 
cell capture. In addition, we explored the feasibility of PA imaging to detect CTCs in 
whole blood. We demonstrated excellent detection sensitivity delineating the distribution 
of hybrid nanoclusters targeting the cancer cells on a porous membrane. The work paved 
the way for a novel and efficient CTC assay which utilizes immunotargeted magneto-
plasmonic nanoclusters for a simultaneous magnetic capture and PA detection of CTCs. 
In Chapter 4, we demonstrated a concept to mediate immune cells with magnetic 
properties and a magnetic field to improve cellular delivery for immunotherapy of cancer. 
We showed that the immune cells were well labeled by our nanoparticle platform based 
either cellular internalization or selective surface targeting approach. None of the 
nanoparticle labeling approaches induced noticeable cytotoxic to immune cells. The 
magnetically engineered cells can be trafficked with an aid of a magnetic field. Thus, our 
results highlight the promise of using our nanoparticle platform as a multifunctional 
probe to manipulate and track the transferred immune cells in vivo and encourage further 
evaluation of therapeutic efficacy in the magnet-guided cellular immunotherapy.  
5.2 FUTURE WORK 
Targeted metal nanoparticles for imaging and delivery are designed to interact 
with specific subsets of cells. It is important to ensure that these nanoparticles are not 
causing long-term toxicity.1, 2 As gold nanoparticles are barely biodegradable, they may 
cause concerns about clinical translation. FDA mandates that contrast agents should be 
cleared in a reasonable time.1 Therefore, one of the future works is to modify the 
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synthetic chemistry of our hybrid nanoparticle platform for efficient body clearance. 
Several studies indicate that the nanoparticles less than 6 nm in diameter can be 
efficiently cleared.1, 3, 4 This is encouraging for us because the size of constituent 
nanoparticles for building the hybrid nanoparticle platform is in the same range. The 
nanocluster formation can be aided by the use of weakly adsorbing biodegradable 
polymers that allows the control of nanocluster size and the enhancement of magnetic 
and optical functionalities.5 The biodegradable polymer stabilizer can degrade over time 
under physiological conditions which leads to disassembly of nanoclusters into sub-6 nm 
constituent nanoparticles6, thus holding the promise for efficient body clearance.  
The high sensitivity of PA imaging enables a new method to detect CTC; 
however, this method should be further tested its accuracy which can be carried out by 
comparison with the current standard detection based on immunofluorescence staining. 
Specifically, the samples can be divided into two groups: half of the samples will be 
examined under PA imaging, whereas the other half of the samples will be stained with 
DAPI, CD45, and CK and observed under fluorescent microscope. The accuracy can be 
determined by comparing the counts of CTCs from PA detection and fluorescent staining. 
Furthermore, lower CTC number, e.g. 1-5 cells per mL blood, is necessary to test 
detection efficiency.7 Ultimately, creating a special magnetic microchip designed for 
simultaneous magnet capture and PA detection would be beneficial for a highly sensitive, 
low cost, facile CTC assay. The design of the microchip will include a fluidic chamber 
which accommodates a porous array at the bottom. The size of the holes should be larger 
than the nanoparticles but smaller the targeted cells. With a magnet field gradient applied 
to the chamber, targeted cells can be retained in the chip whereas the free nanoparticles 
will be filtered out through the pores and unlabeled cells will be washed away. Then, the 
captured CTCs can be detected using PA imaging through an acoustically transparent 
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window on the top of the flow chamber. Signal intensity from PA imaging and size/shape 
of identified objects will be used as discriminative parameters in recognizing and 
counting labeled cancer cells. After PA imaging, CTCs can be collected through the 
outlet after removal of the magnet for downstream molecular analyses. 
A new magnetic approach to enhance cell delivery of immunotherapy of cancer 
has been proposed to overcome the poor homing efficiency of transferred cells. A series 
of in vitro experiments demonstrated highly magnet-controlled manipulation of labeled 
immune cells. However, a systemic in vivo evaluation will be needed to validate the 
feasibility of this magnetic approach under more sophisticated physiological conditions. 
Furthermore, the trafficking of the labeled immune cells in vivo can be monitored by a 
variety of imaging modalities, such as photoacoustic imaging, MRI, or X-ray imaging, 
since the hybrid nanoparticles provide very good contrast for them. Ultimately, the 
magnetic approach should be investigated whether the enhancement of cytotoxic T 
lymphocyte recruitment can be exploited as a fatal attraction for tumor therapy.  
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